Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in non-human primates

Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in non-human primates | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in non-human primates Benjamin Dehay, Joanna Sikora, Sandra Dovero, Rémi Kinet, Marie-Laure Arotcarena, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3845030/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 01 Aug, 2024 Read the published version in npj Parkinson's Disease → Version 1 posted 11 You are reading this latest preprint version Abstract Lysosomal impairment is strongly implicated in Parkinson's disease (PD). Among the several PD-linked genes, the ATP13A2 gene, associated with the PARK9 locus, encodes a transmembrane lysosomal P5-type ATPase that acts as a lysosomal polyamine exporter. Mutations in the ATP13A2 gene were primarily identified as the cause of Kufor-Rakeb syndrome (KRS), a juvenile-onset form of PD. Subsequently, an increasing list of several homozygous and compound-heterozygous mutations has been described. These mutations result in truncation of the ATP13A2 protein, leading to a loss of function but surprisingly causing heterogeneity and variability in the clinical symptoms associated with different brain pathologies. In vitro studies show that its loss compromises lysosomal function, contributing to cell death. To understand the role of ATP13A2 dysfunction in disease, we disrupted its expression through a viral vector-based approach in nonhuman primates. Here, in this pilot study, we injected bilaterally into the substantia nigra of macaque monkeys, a lentiviral vector expressing an ATP13A2 small hairpin RNA. Animals were terminated five months later, and brains were harvested to evaluate cerebral pathological markers known to be affected in KRS and PD. We characterised the pattern of dopaminergic loss in the striatum and the substantia nigra, the regional distribution of α-synuclein immunoreactivity in several brain structures, and its pathological status (i.e., S129 phosphorylation), the accumulation of heavy metals in nigral sections and occurrence of lysosomal dysfunction. Our findings show that lentivirus-mediated ATP13A2 silencing can induce significant and ongoing degeneration in the nigrostriatal pathway, α-synuclein pathology, and iron accumulation in nonhuman primates. Biological sciences/Neuroscience/Diseases of the nervous system/Parkinson's disease Biological sciences/Neuroscience/Diseases of the nervous system/Neurodegeneration Health sciences/Diseases/Neurological disorders/Neurodegenerative diseases/Parkinson's disease lysosome neurodegeneration synuclein Parkinson's disease nonhuman primate Figures Figure 1 Figure 2 Figure 3 Figure 4 INTRODUCTION The ATP13A2 gene (OMIM#610513) encodes a transmembrane lysosomal 5 P-type ATPase. The first mutations described in ATP13A2 cause an autosomal recessive form of early-onset parkinsonism called Kufor-Rakeb Syndrome (KRS, OMIM#606693) 1 and neuronal ceroid lipofuscinosis (NCL, OMIM#256730), later assigned to PARK9 locus. The clinical spectrum of KRS comprises parkinsonism, dystonia, supranuclear gaze palsy, and severe cognitive decline 2 . Brain MRI of KRS patients revealed generalised atrophy and putaminal and caudate iron accumulation, classifying KRS amongst neurodegeneration with brain iron accumulation (NBIA) 3 . NCL is a lysosomal storage disorder (LSD) that belongs to a genetically heterogeneous group of rare neurodegenerative diseases resulting from an accumulation of lipopigments, predominantly in the brain and retina. Typical clinical manifestations of these LSDs include progressive motor and cognitive impairment, seizures, and visual impairment or blindness. The outcome is invariably fatal, usually during the second or third decade. Today, there is a growing list of homozygous and compound-heterozygous mutations 4,5 linked to the truncation of the ATP13A2 protein, resulting in a loss of its functional capabilities. Remarkably, all mutations associated with KRS that have undergone experimental scrutiny exhibit varying degrees of interference with ATP13A2 function. These disruptions are brought about through diverse mechanisms, including nonsense-mediated messenger RNA decay, protein mislocalization, and premature degradation of protein products by the proteasomal system. However, the phenotypic spectrum associated with genetic variants in ATP13A2 now becomes more and more complex since the (partial) loss of function leads to a whole range of clinical phenotypes, including previously comprised of KRS, NCL, multiple system atrophy (MSA) 6 , hereditary spastic paraplegia (SPG78) 7–9 , and juvenile-onset amyotrophic lateral sclerosis (ALS) 10 , as supported by both genetic and functional data, which makes the ATP13A2 gene a puzzling gene. To date, neuroprotective strategies for all those diseases that would stop or slow down the yet unrelenting ATP13A2-related degenerative process are eagerly awaited. Mechanistic studies have previously reported that KRS-linked mutations in ATP13A2 lead to several lysosomal alterations in ATP13A2 KRS patient-derived fibroblasts, including impaired lysosomal acidification, decreased proteolytic processing of lysosomal enzymes, reduced degradation of lysosomal substrates and diminished lysosomal-mediated clearance of autophagosomes 11–14 . In addition, ATP13A2 levels are decreased in nigral dopaminergic neurons from sporadic Parkinson’s disease (PD) patients 11 , a result later corroborated by others 15 . Overall, those results unravel an instrumental role for ATP13A2 on lysosomal function and cell viability. Recently, the cellular function of this P-type ATPase was unmasked 14 as a lysosomal H + , K + -ATPase, and polyamine exporter, confirming its link to protein degradation via the lysosomal machinery 11–13,16 and metal homeostasis (as reviewed in 17 ), which cryo-electron microscopy has further structurally characterised 18–22 , altogether improving our understanding behind ATP13A2-associated functions. To date, only one human brain neuropathological study from one ATP13A2-mutant KRS patient is available 2 , reporting widespread neuronal and glial lipofuscin accumulation and sparse iron deposits in several brain areas, with skin and muscle of KRS subjects containing electron-dense lamellated structures 23 . To decipher the pathological consequences of ATP13A2 deficiency, a vast spectrum of model organisms has been used, from yeast 24 to different animal species (fly 25 , worm 26 , zebrafish 27 , and mouse 28,29 ). Atp13a2 null mice exhibit increased autofluorescence in multiple brain regions, indicative of lipofuscin accumulation and modest age-related motor dysfunction preceded by neuropathological changes, including gliosis, accumulation of ubiquitinated protein aggregates, and endolysosomal abnormalities. Still, no overt neurodegeneration and iron accumulation have been observed. Additionally, a recessive mutation has been described in canine ATP13A2, causing adult-onset NCL in Tibetan terriers where autofluorescent cytoplasmic inclusions were detected in brain tissue consistent with NCL 30 . Altogether, model organisms used until now with the (partial) loss of ATP13A2 exhibit subtle age-dependent motor dysfunction, which at the cellular level correlates to lysosomal impairment. In mammalian model organisms, gliosis and lipofuscinosis were additional from ATP13A2 deficiency. These findings demonstrate the significance of lysosomal functionality at the core of ATP13A2 depletion. However, to truly decipher the clinical spectrum observed in humans, the role of ATP13A2 in neuronal survival, and how this dysfunction leads to neurodegeneration, we hypothesised that, in nonhuman primates, a species phylogenetically closer to humans, targeted silencing of ATP13A2 in dopaminergic neurons might result in neuronal death, α-synuclein pathology, metal dyshomeostasis, and autophagy dysfunction. To this end, in a proof-of-concept pilot study, we injected bilaterally into the substantia nigra of macaque monkeys a lentiviral vector-mediated short-hairpin RNA (LV-shRNA) to downregulate the expression of ATP13A2. Five months after administration, we observed nigrostriatal neurodegeneration associated with α-synuclein pathology, nigral iron accumulation, and autophagy lysosomal pathway (ALP) disturbances upon LV-mediated ATP13A2 silencing. RESULTS Nigral ATP13A2 depletion induces nigrostriatal neurodegeneration. The lentiviral vector (LV) system is highly effective for delivering short hairpin RNA (shRNA) expression cassettes 31 associated with no indications of increased non-human primate (NHP) tissue damage or inflammatory responses 32 . We used a functional and efficient sequence of shRNA targeting human ATP13A2 cloned into an LV plasmid, which displayed a 95% reduction in ATP13A2 levels by immunoblotting, as previously reported 11 . In addition, we showed that LV-mediated ATP13A2 knockdown in primary mesencephalic dopaminergic neurons resulted in neurotoxicity 11 . To further determine the pathological consequences of silencing ATP13A2 in a species closer to humans, adult macaque monkeys received bilateral stereotactic injections (10µl per hemisphere) of LV encoding shATP13A2 into the SNpc ( Supplementary Fig. 1A ). Five months after administration, monkeys were tested to evaluate the transduction efficiency and the integrity of the nigrostriatal pathway. ATP13A2 immunofluorescence revealed a significant decrease in ATP13A2 levels in TH-positive dopaminergic neurons of the shATP13A2 versus the control group ( Supplementary Fig. 1B ). We confirmed a ~ 60% decrease in endogenous ATP13A2 after shATP13A2 LV was obtained by immunoblot of homogenised formalin-fixed tissues collected on sections in the SNpc ( Supplementary Fig. 1C ). shATP13A2-injected monkeys displayed a significant decrease in TH immunoreactivity in the SNpc (Fig. 1 A), which was accompanied by a significant reduction in striatal dopaminergic innervation both in the putamen and caudate nucleus (Fig. 1 B). Stereological counts showed that shATP13A2-injected animals exhibited a ~ 28% TH-positive cell loss in the SNpc (Fig. 1 A). However, no overt parkinsonism was observed because the extent of the lesion remained below the threshold for the onset of motor symptoms, i.e., 45% cell loss 33 . At the striatal level, LV-shATP13A2 injection induced a significant 30% loss of TH immunoreactivity in the caudate nucleus ( Fig. 1 B ) and 45% in the putamen ( Fig. 1 B ) . AADC, the enzyme that decarboxylates L-DOPA into dopamine ( Fig. 1 B ) , and striatal DAT immunostaining ( Fig. 1 B ) were also both reduced, with a mean difference between groups of 60–70% (AADC) and 35% (DAT) in the caudate and putamen respectively. ATP13A2 depletion alters α-synuclein homeostasis in substantia nigra. We then investigated the consequences of ATP13A2 depletion-induced nigrostriatal degeneration on nigral α-synuclein (α-syn) protein expression. We performed a quantitative post-mortem analysis of total α-syn (syn211 antibody) and phosphorylated α-syn at S129 (EP1536Y) levels as a surrogate marker of the presence of α-syn pathology 34,35 within the SN. In contrast to predictions from in vitro studies, we observed no changes in total α-syn levels in SN (Fig. 2 A ) , while the α-syn pathogenic form, i.e., S129 phosphorylated α-syn, increased in DA neurons in shATP13A2-injected animals (Fig. 2 B). Even though we could not obtain fresh tissues from the substantia nigra of monkeys for Western blotting analysis, we performed protein extraction from formalin-fixed substantia nigra to further investigate α-syn pathology. Notably, our findings indicated that there were no discernible changes in total α-syn levels when using the syn211 antibody on mesencephalic total protein extracts, aligning with the results obtained from the immunohistochemical analysis, which also showed a significant accumulation of phosphorylated α-synuclein (pSyn) (Fig. 2 C). The absence of modifications in total α-syn levels could potentially be attributed to a conformational alteration in the α-syn protein, causing it to adopt a pathological form that conceals the syn211 epitope (located within amino acids 121–125) 36 . Consequently, this post-translational modification might alter its conformation and render it undetectable by the syn211 antibody while remaining accessible to the anti-p-S129 α-synuclein antibody. This phenomenon could account for the observed increase in one species coinciding with no changes in the other. To further examine the distribution of α-syn, we performed triple immunofluorescence at the nigral level with the well-established dopaminergic marker TH, the lysosomal marker LAMP1 and the Syn211 antibody ( Supplementary Fig. 2 ). We observed clustered compartments stained for LAMP1 with some clustering with α-syn in dopaminergic neurons of shATP13A2-injected animals compared to controls, suggesting a possibly aggregated form of α-syn consisting of the accumulation of pSyn, as detected by immunohistochemical and biochemical assays. Altogether, these results indicate α-syn build-up with a change in intracellular staining pattern and increased pSyn protein expression in SN five months after nigral LV-shATP13A2 injection. Accumulation of lysosomal-related vesicles in dopaminergic neurons of shATP13A2-injected animals. In vitro studies suggest that loss of ATP13A2 function leads to a rise in the number and size of lysosomes 11,12 , potentially as compensation for poor lysosomal function. Thus, we evaluated lysosomal-related vesicle number, surface and intracellular distribution in surviving nigral TH-positive neurons in vivo by segmentation analysis of confocal images. Following cell segmentation into whole cell area, perinuclear and cytosolic regions of interest (ROI) and detection of LAMP2- and LC3-positive vesicles, we calculated the average number and area of LAMP2- and LC3-positive puncta (Fig. 3 ). Consistent with in vitro reports, we found an increased number of LAMP2-positive lysosomes (Fig. 3 A) and an increased number and surface of LC3-positive autophagosomes (Fig. 3 B) in surviving nigral TH-positive neurons, consistent with a perturbation of these organelles. Strikingly, we observed an accumulation of both LAMP2- and LC3-positive puncta in the perinuclear area, which might indicate an accretion of immature and undegraded autolysosomes at this location as ATP13A2 inactivation is associated with impairment of autophagosome-lysosome fusion 25 . These findings are consistent with previous in vitro studies and may reflect compensatory changes in the ALP following improper clearance of lysosomal substrates. Lipofuscin is a pigmented, heterogeneous byproduct of failed intracellular catabolism conventionally found within lysosomes or the cytosol in the brains of patients with ATP13A2 mutations 23 . We next attempted to examine the presence of lipofuscin in the nigral sections. Compared with control animals, LV-shATP13A2 monkeys showed an increased deposition of autofluorescent storage material in the substantia nigra five months after nigral LV-shATP13A2 injection (Supplementary Fig. 3) . Overall, these data indicate a dysfunction of the ALP associated with an accumulation of lipofuscin deposits characteristic of NCL. ATP13A2 depletion alters metal homeostasis in substantia nigra. Because the loss of ATP13A2 function is associated with dysregulated metal homeostasis in different experimental models 24,26,37,38 and KRS patients 39,40 , we measured nigral heavy metal levels by synchrotron radiation x-ray fluorescence (SR-XRF) (Fig. 4 A) as previously described 41 . Iron (Fig. 4 B), sulfur (Fig. 4 C), and manganese (Fig. 4 D) concentrations were significantly increased in LV-shATP13A2 monkeys compared to control animals. In the case of copper, concentrations were statistically decreased in LV-shATP13A2 monkeys compared to control monkeys (Fig. 4 E), whereas no statistical differences were observed for calcium (Fig. 4 F) and zinc (Fig. 4 G). Interestingly, iron concentrations were a three-fold increase in shATP13A2 monkeys, reminiscent of human pathology 39,40,42–44 . Next, we sought to determine the cell-type specificity and distribution of iron accumulation in the SN. We performed a triple immunofluorescence with the dopaminergic neuronal marker TH, the microglial marker Iba1, and Ferritin, the main iron-storage protein. We detected an increase of ferritin-positive cells in LV-shATP13A2 monkeys compared to controls (Supplementary Fig. 4) , and we observed increased expression in iron-storage protein ferritin in both Iba1-positive microglia (Supplementary Fig. 4A) and TH-positive neurons (Supplementary Fig. 4B) . Upon closer examination, the iron-positive cells displayed distinctive morphological features consistent with activated microglia, including a compact soma and numerous thin processes 45 , indicative of an ongoing inflammatory response. This immunofluorescence analysis suggests that iron accumulates in dopaminergic neurons and microglial cells, with more abundant smaller puncta distributed in the microglia. DISCUSSION Decreased ATP13A2 expression in the substantia nigra through an LV-shRNA strategy leads to major pathological features in nonhuman primates reminiscent of PD pathology. Knockdown of ATP13A2 by ~ 60% in nigral dopaminergic neurons affected their integrity, as evidenced here by (i) changes of α-synuclein immunoreactivity associated with an increase of one of its pathological forms (i.e., S129 phosphorylation); (ii) a dyshomeostasis in heavy metals and (iii) occurrence of ALP alterations. All these features were prominent in the SN of shATP13A2-injected NHP, resulting in a loss of striatal dopaminergic terminals and SNpc dopaminergic neurons. Relevant to KRS, we also show that silencing of ATP13A2 induces iron accumulation in the substantia nigra. These observations indicate an instrumental role for ATP13A2 deficiency in lysosomal function, α-synuclein and heavy metal homeostasis, and eventually cell viability. This new PD model provides a mechanistic framework that recapitulates some key pathological features of ATP13A2-related diseases. However, it is essential to acknowledge the limitations inherent in this study, foremost among them being the relatively small cohort sizes, typically consisting of only 2 to 3 animals per group. Nevertheless, this size is commonly recognised as a standard size for pilot studies in non-human primate (NHP) research, grounded in scientific considerations and ethical constraints 46 . Notably, our study's statistical power is diminished, a common characteristic in NHP research, where a significant proportion often involves minimal animal numbers per group, typically ranging from 2 to 4 individuals, due to cost and difficulty accessing monkeys. With two groups of two to three monkeys, either LV-shATP13A2-injected or noninjected, it is challenging to obtain for each variable homogenous results that allow giving definitive answers. Some endpoints do not reach statistical significance because of the small sample size. Hence, the importance of the Gardner–Altman plots that focus upon the effect size of the difference, when any. Many studies conducted by our team and other colleagues working on NHPs have generally used these types of low group sizes 47–57 . Our team is, however, known to involve a much larger number of NHPs when moving to definitive studies 41,58–61 that have always confirmed experiments with lower n. To investigate the pathological consequences of ATP13A2 deficiency, a vast panel of models of ascending complexity, i.e., in human dopaminergic neuroblastoma-derived cells, mesencephalic primary cultures, mice, and dogs, have been developed. However, in ATP13A2 knockout mice, behavioural phenotype impairment and pathophysiological abnormalities are not detectable until old age (20- to 29-month-old), without overt neurodegeneration 28,29 , suggesting the involvement of strong compensatory mechanisms in transgenic mice. Dogs with ATP13A2 mutations show clinical signs of NCL similar to those of KRS patients, but without parkinsonism, associated with astrogliosis and autofluorescent storage material in nervous and cardiac tissues at an average age of 6 years, progressively worsening over time 30,62,63 . A striking result of the current study is the efficacy of the induction of dopaminergic neurodegeneration over five months, corresponding to a short duration for a study in nonhuman primates. We hypothesise that follow-up long-term studies are required to observe the occurrence of a full spectrum of behavioural deficits, including progressive motor and cognitive impairment, i.e., when the threshold of the nigrostriatal lesion for manifest PD will be reached 33 . Additionally, we should also target other brain regions to extend the disease modelling panel associated with ATP13A2 loss of function. A second aspect to be envisioned for future studies is to compare the effects obtained with an adeno-associated virus (AAV)-based strategy. Several advantages can be emphasised by moving to AAV due to its unique biological and biophysical properties. First, AAV is compatible with the viral capacity to carry recombinant DNA such as shRNA. Second, AAV has a diffusion advantage over LV due to its particle size, which is 25 nm in diameter, whereas LV particles are no less than 100 nm in diameter. Third, specific serotypes of AAV share the ability to cross the blood-brain barrier. They may be delivered through various administration routes, making them a powerful tool for genetic material delivery to the CNS 64–66 . Fourth, AAV has proved safe and effective in preclinical and clinical settings and has been the virus of choice for developing gene therapies for PD 67 . While this proof-of-concept study is encouraging, pending questions await future investigation in additional animals. To date, it is evident that numerous neurological disorders have been linked to ATP13A2 with diverse and complex neurological deficits, complicating our understanding of ATP13A2. However, the fact that mutations in a single lysosomal gene result in such a diversity of disease phenotypes suggests that lysosomal burden is a common thread running amongst them. Therefore, deciphering the ATP13A2-dependent cellular roles and pathways would enhance our understanding of brain physiology and the broader mechanisms underpinning neurodegeneration. First, one aspect to investigate in future studies will be the analysis of polyamine levels. Recent studies demonstrated the polyamine transport function of ATP13A2 14 , which may support heavy metal chelation 68 and provide antioxidative effects 69 . Polyamine levels decline with ageing and are altered in PD patients. Analysing polyamine levels in this new experimental animal model should provide valuable information regarding the precise role of polyamines in PD, KRS, and beyond. Second, in humans, ATP13A2 mutations cause neurodegeneration with brain iron accumulation 39 ; in particular, KRS patients present iron deposits in the brain 39,40 whereas, in mammalian cells, ATP13A2 expression and transport activity protect against several heavy metals, such as manganese, zinc, and iron toxicity 37,70 . Our study measured an iron increase of over 300%, demonstrating a close relationship between iron accumulation and ATP13A2 depletion. Several experiments proposed that the ferric iron load accelerates α-synuclein aggregation 71 , and an increase in iron levels plus a decrease in ferritin can contribute to nigral degeneration 72 . An increased iron burden has been found in early PD stages in the SN 42–44,72 . The pathological consequences of the increased iron SN burden could contribute to α-syn pathology, as we observed an increased nigral pSyn expression. Noteworthy, we also observed a significant increase in manganese in the SN, consistent with the fact that ATP13A2 has been reported to be involved in manganese homeostasis 24,26,38 . This result is reminiscent of previous reports showing that ATP13A2 protects cells against manganese toxicity by transporting manganese into lysosomes; however, this protection is lost in the case of mutations in this gene 37 . A recent study showed that ATP13A2 polymorphism could be a risk marker for the neurotoxic effects of manganese in humans 73 . Both of our findings are of interest regarding the work of Fleming and colleagues that show increased manganese and iron in ATP13A2 knockout mice administered with manganese chloride compared to treated wild-type mice but also increased α-synuclein aggregation and higher lipofuscin deposits in the SN 74 . Of note, the copper reduction is also of interest and deserves further studies as it has been reported to be reduced in human SN dopaminergic neurons of PD and incidental Lewy body disease cases 75 . Overall, we show that ATP13A2 depletion triggers PD/KRS-related features in nonhuman primates, with stimulating perspectives for understanding human ATP13A2 pathology per se . Further studies are needed to extend our observations and appreciate the full spectrum of behavioural and pathological outcomes of ATP13A2 deficiency. Understanding the complex contribution of the dysfunctional or absent lysosomal ATP13A2 protein to ALP dysfunction, heavy metal dyshomeostasis, and neurodegeneration would likely open new therapeutic opportunities for slowing down the degenerative process in PD/KRS patients. METHODS Ethics Statement All experimental protocols comply with the Council Directive of 2010 (2010/63/EU) of the European Community and the National Institute of Health Guide for the Care and Use of Laboratory Animals. The proposed research has received approbation from the French Ethical Committee for Animal Research CE50 (agreement number: 50120102-s). Recombinant LV-shRNA plasmid and virus production shRNA lentiviral plasmids were purchased from Sigma-Aldrich. shRNAs were validated based on the Genbank human ATP13A2 sequence NM_022089. All sequences were BLAST confirmed for specificity. Synthetic DNA encoding shRNA sequences targeting human ATP13A2 were cloned into shRNA lentiviral plasmids (pLKO.1-puro) under the control of the U6 promoter. shRNA lentiviral plasmids were transfected into BE( 2 )-M17 cells for 48 hours to determine the level of knockdown of gene expression by immunoblotting 11 . The ATP13A2 shRNA-expressing viruses have been tested as described above. The virus titers were 6.73x10 8 pI/ml for ATP13A2 shRNA. The shRNA sequence used in the study is CCGGGCCCATCAACTTCAAGTTCTACTCGAGTAGAACTTGAAGTTGATGGGCTTTTTG. Lentiviral vector production was done by the service platform for lentiviral vector production “Vect’UB’ of the TMB-Core of Bordeaux University. A lentiviral vector was produced by transient transfection of 293T cells according to standard protocols. In brief, subconfluent 293T cells were co-transfected with the lentiviral genome (psPAX2) 76 , with an envelope coding plasmid (pMD2G-VSVG) and with vector constructs by calcium phosphate precipitation. LVs were harvested 48 hours post-transfection and concentrated by ultracentrifugation. Viral titers of pLV lentivectors were determined by transducing 293T cells with serial dilutions of viral supernatant, and EGFP expression was quantified 5 days later by flow cytometry analysis or provirus copies number by qPCR method. Animals and Stereotactic Injections Two female adult rhesus monkeys ( Macaca mulatta ) weighing ∼6–7 kg (9–10 years old) were used in this study. The monkeys were housed in the animal facility of the Institute of Neurodegenerative Diseases (UMR CNRS 5293) under standard conditions (12/12 h day/night cycle, ∼60% humidity, and ∼22°C). Tissues from 4 to 6 additional age-matched control animals were used for post-mortem experiments when needed and available 77 . Bilateral intranigral LV injections of 10µl were performed with electrophysiological guidance considering the line passing through the anterior (AC)-posterior (PC) commissures as a reference: -7mm posterior to AC, -4mm below the AC-PC line, and 3mm lateral from midline. At the end of the experiment (5 months post-injection), as previously described 41,56,60 , all monkeys were euthanised by sodium pentobarbital overdose (150mg/kg iv), followed by perfusion with saline solution (containing 1% heparin) and 4% paraformaldehyde, and brains were quickly removed and processed for histological studies. Histological Analysis Dopaminergic neurodegeneration assessments To assess the effect of ATP13A2 silencing on dopaminergic neurones and fibres, TH (tyrosine hydroxylase), AADC (Aromatic L-amino acid decarboxylase), and DAT (Dopamine Transporter) immunohistochemistry and quantifications were performed on striatal and SNpc sections as previously described 41,56,60 . For TH staining, anterior striatum (pre-anterior commissure) sections and a whole rostrocaudal series (1 to 12) encompassing the SNpc were selected. For AADC and DAT staining, anterior striatum (pre-anterior commissure) sections were used. Sections were incubated with mouse monoclonal TH antibody (Millipore, MAB318, 1:5000), rabbit polyclonal AADC antibody (Merck AB136, 1:1000), or rat monoclonal DAT antibody (Merck MAB369, 1:500) for one night at room temperature (RT) and revealed the next day with the corresponding peroxidase EnVision secondary antibody, followed by DAB visualisation. SNpc sections were mounted on gelatine-coated slides, counterstained with 0.1% cresyl violet solution, dehydrated and cover-slipped. Striatal sections were mounted on gelatine-coated slides, dehydrated and cover-slipped. Striatal sections were analysed by optical density (OD) in the caudate nucleus and putamen. The slides were scanned using Epson Expression 10000XL high-resolution scanner. Images were analysed using ImageJ open-source software (version 1.53) to compare mean grey levels in the caudate nucleus and putamen. TH-positive neurons of the SNpc were counted by stereology blind about the experimental condition using a Leica DM6000B microscope coupled with the Mercator software (IMASCOPE, France). The SNpc was delineated for each slide, and dissector probes for stereological counting (100x80µm spaced by 600x400µm) were applied to the map obtained. Each TH-positive cell with the nucleus included in the probe was counted following the stereological rules of exclusion 41,56,60 . The total number of TH-positive neurons in the whole SNpc was then assessed per hemisphere using the optical fractionator method. α-Synuclein pathology assessment α-synuclein status was assessed with a mouse monoclonal antibody raised against human α-syn (1:1000, ThermoFisher [Syn211], 32-8100) and another against phosphorylated α-syn (EP1536Y, Abcam, ab51253, 1:5000) as previously described 41,56,60 . Briefly, selected sections of all animals were explicitly identified and incubated in the same well to allow direct comparison of immunostaining intensity. Sections were incubated overnight at room temperature with the antibodies. The following day, the revelation was performed with the corresponding peroxidase EnVision secondary antibody followed by 3,3′-diaminobenzidine (DAB, DAKO, K346811-2) incubation. Sections were then mounted on gelatinized slides, counterstained with 0.1% cresyl violet solution, if necessary, dehydrated, and cover-slipped until further analysis. Slides were scanned with a high-resolution scanner (Panoramic Scan II, 3DHISTECH Ltd, France) at x20 magnification and on five layers spaced by 1.4µm each. Quantifications were estimated by immunostaining-positive surface quantification at regional levels with the Mercator software (IMASCOPE, France), as previously described 41,56,60 . The “surface” is an additional quantification method used in tissue sections. For these analyses, a specific staining process was used to keep all tissues together in the same solution during the staining process. Then, high-resolution whole colour slide images were acquired with the 3D Histech Panoramic Scanner at 20X magnification, with 5 layers in extended mode. Each image was opened in the off-line MERCATOR PRO 7.12.3 software (Explora Nova, France), and all regions of interest were mapped. The same brightness and contrast rules were systemically applied to the RGB pictures to optimise the staining’s details without any image saturation. The colour thresholding tool was then used to select the threshold corresponding to the brown colour revealed by the DAB staining. The threshold was established based on the intensity of the staining to detect the maximum DAB staining. The file of the threshold parameters was saved and applied to all measurements for each animal/staining. Before performing the quantification, the threshold was randomly applied to some images of different treatment groups to verify the accuracy of the settings. In each region, the software extracted the surface corresponding to the threshold defined. The “surface” parameter was finally expressed as a ratio of the total surface of each area of interest. This parameter has been previously used and published 78 . Immunofluorescence and Image Analysis To assess ATP13A2 expression and autophagy-related markers (i.e., autophagosomes and lysosomes), nigral monkey sections were incubated simultaneously with two antibodies: a mouse monoclonal antibody against TH (Millipore, MAB318, 1:5000), and, either a rabbit monoclonal antibody against ATP13A2 (Novus Bio, NB110-41486, 1:250) or a rabbit monoclonal against human LAMP1 (Genetex, GTX62434, 1:1000) or LAMP2 (Santa Cruz Biotechnology, sc-18822, 1:1000) or LC3 (NB100-2220, Novus Biological 1:1000) or human α-syn (1:1000, ThermoFisher [Syn211], 32-8100) for one night at room temperature. Incubation with secondary antibodies was done sequentially with a goat anti-mouse AlexaFluor 488 (Invitrogen, A28751, 1:400) or a goat anti-rabbit AlexaFluor 568 (Invitrogen, A11036, 1:400) 1h30 at room temperature. Sections were mounted on non-gelatinised slides, and cover slipped using fluorescent mounting media without DAPI (Vector Labs). Images were acquired using a Zeiss SP5 confocal microscope. For LAMP2 and LC3 count and area analysis in TH-positive cells at 5 months post-injection, image analysis was performed in Fiji/ImageJ. All image acquisitions and analyses were performed blinded to the researcher. Image analysis was performed in Fiji/ImageJ using custom scripts (available at https://github.com/SoriaFN/Lysosome_analysis ). Cells were segmented by manual cell selection using the TH channel. The mask was then applied to the LAMP2 and LC3 channels, where LAMP2 and LC3 staining was quantified by automatic thresholding followed by binarisation. Total staining was then normalised per cell. For subcellular localisation analysis, cytoplasmic and nuclear ROIs were manually segmented using the TH channel of single z-planes where the nucleus was clearly visible. To prevent a bias due to low cytoplasmic area and to ensure that the comparisons were made between cells with similar cytoplasmic ROIs, the analysis was subsequently performed only in cells where the ratio of cytoplasmic to nuclear ROI area was 2:1. Lysosomal-related puncta were segmented from the LAMP2 or LC3 channel, and the average number and area from the nucleus centre to the centre of mass of each lysosomal ROI was calculated. Finally, to estimate the distance to the nucleus border, the average radius of an ellipse fitted to the nuclear ROI was subtracted from the distance to the nucleus centre. To assess ferritin pattern expression, each nigral monkey section punches was made from free-floating sections and mounted on the same slide to compare the pattern between TH, Iba1 and ferritin-expressing cells in SNpc. The resulting glass slide was incubated simultaneously with a mix of antibodies, including chicken anti-TH (Abcam, ref ab76442), goat anti-Iba1 (Abcam, ref ab5076) and rabbit anti-ferritin [EPR3004Y] (Abcam, ref ab75973), all diluted at 1:1000 and incubated for one night at room temperature. Incubation with secondary antibodies was done after thorough rinses, with a mix of donkey fluorescent secondary antibodies raised against the different species (respectively anti-chicken AlexaFluor 568 (Invitrogen, A11041), anti-goat AlexaFluor 647 (Invitrogen, A21447) and anti-rabbit AlexaFluor488 (Invitrogen, A21206) diluted at 1:500 and incubated one hour at room temperature. After several rinses with PBS, a nuclear stain was made with 1:5000 diluted Hoechst solution for 30 seconds, and sections were then coverslipped using ProlongGlass fluorescent mounting media (Thermo Fischer, ref P36984). Images were acquired using a 3D-HISTECH Pannoramic Scan II with 20X objective and extended focus mode (5 layers and 7 steps). Lipofuscin imaging For imaging of lipofuscin, untreated free-floating nigral slices were mounted with a Vectashield Antifade Mounting Medium to observe lipofuscin autofluorescence. Images were acquired using a Leica DM6 CFS TCS SP8 confocal microscope at x63 magnification, with an excitation of 500nm and an emission of 600-650nm. Analysis was performed through ImageJ Fiji. Biochemical Analysis Protein Extraction and immunoblot analysis We used 2 mm 3 formalin-fixed tissue per animal. Tissue patches were extracted using the Qproteome FFPE TissueKit (Qiagen) 79–81 and then quantified using the Lowry method (Biorad RC DC Protein Assay Kit) following the manufacturer's instructions. Based on total protein concentrations calculated from the assay, aliquots of tissue lysates corresponding to 20µg were prepared for each structure in Laemmli buffer (Tris-HCl 25mM pH 6.8, glycerol 7.5%, SDS 1%, DTT 250mM and bromophenol blue 0.05%). For immunoblot analysis, samples were then boiled at 100°C for 5min and loaded into a 12% SDS-PAGE gel, followed by electrophoretic transfer onto 0.2 µm nitrocellulose membranes (Bio-Rad, Hercules, CA, United States). Membranes were blocked in phosphate buffer saline (PBS) with 5% dry skimmed milk and probed with an antibody against ATP13A2 (Novus Bio, NB110-41486, 1:1000) overnight. Anti-β-actin (1:10 000, Sigma, A5441) was used to control equal loading. Appropriate secondary antibodies coupled to peroxidase were revealed using a Super Signal West Pico Chemiluminescent kit (Immobilon Western, Chemiluminescent HRP substrate, Millipore) and analysed with Image Lab software 5.0 (Bio-Rad, Hercules, United States). The dot blot analysis was performed as previously described 82 . After heating at 100°C for 5 min, 20 µg of protein extract was diluted in buffer (25 mM Tris-HCl, 200 mM Glycine, 1% SDS) and filtered through a nitrocellulose membrane (Bio-Rad, 0.2µm pore size). Membranes were then saturated in 5% dry milk before incubation with total α-syn (1:1000, ThermoFisher [Syn211], 32-8100) and anti-phosphorylated-α-syn at Ser129 (1:5000, Abcam [EP1536Y], ab51253). Revelation was done as described above. SR-XRF microscopy elemental mapping of brain tissue cryosections The synchrotron experiments were carried out at the Diamond Light Source, Harwell Science and Innovation Campus (Didcot, UK) with 3-GeV energy of the storage ring and 300-mA currents with top-up injection mode. All SR-XRF microscopy investigations reported herein were carried out on the microfocus spectroscopy beamline (I18). The micro-XRF elemental mapping was acquired at room temperature with an incident x-ray energy set to 12 keV using a Si(111) monochromator. This resulted in an x-ray photon flux of 2 ×10 11 photons/s. The SN cryostat section (50µm in thickness) of each animal was collected from free-floating sections and mounted onto an x-ray transparent metal-free 4-µm-thick Ultralene foil (SPEX CertiPrep, Metuchen, NJ, USA) secured to a customised polyetheretherketone (PEEK) holder ensuring contamination-free samples and reduced x-ray scattering contribution. The samples were then left and kept at room temperature in a moisture-free box until used for analysis. The samples were affixed to a magnetic plate connected to the sample stage of the microfocus beamline. The four-element Si drift Vortex ME4 energy-dispersive detector (Hitachi High-Technologies Science America), with Xspress 3 processing electronics, was operated in the 90° geometry; hence, it minimizes the background signal. The sample-detector distance was fixed (75 mm). The sample was held at 45° to the incident X-ray beam and raster in front of the beam while the XRF spectra were collected. An area of 500 µm by 500 µm within the SNpc was mapped for each sample with a step size that matches the beam size (5 µm) and a dwell time of 1 s per pixel due to the low concentration of the element. A thin (100 µm) pellet of the National Institute of Standards and Technology (NIST) standard reference materials SRM1577c (bovine liver material, NIST, Gaithersburg, MD, USA) was measured to calibrate experimental parameters as well as a thin-film XRF reference material (AXO DRESDEN GmbH) with nanoscale uniform mass depositions in the range of ng/mm 2 . This was followed by elemental quantification calculated using the Fundamental Parameters (FP) approach through the open-source software PyMCA 83 , in which the reference material and the sample are modelled in terms of main composition, density, and thickness. The fluorescence spectrum obtained from each pixel was fitted, the elemental concentration (micrograms per gram of dry weight or parts per million) maps were generated, and an average elemental concentration of the SNpc regions was obtained. Statistical Analysis For all experiments, comparisons among means were performed using raw data Student's unpaired t-test (GraphPad Prism 10.0, San Diego, CA). Statistical significance was set at p < 0.05. The debate about the need to move beyond p-value is raging. Data must be further analysed with estimation graphics 84 emphasising the effect size. Therefore, all data appear as estimation graphics called ‘Gardner–Altman plots’: on the left of each graph, data of controls and sh-ATP13A2 groups are presented as scatter plots showing the observed values along with the defined descriptive statistics (mean ± standard deviation). Each dot represents one hemisphere of the control (shade of black) and shATP13A2-injected NHPs (shade of red). On the right of each graph is a contrast graph using the different axes to display an effect size, which means difference. Horizontally aligned with the mean of the test group, the mean difference is indicated by the black circle. The black vertical line illustrates the 95% confidence interval (CI) of the mean difference. Given the observed data, the curve shows the resampled distribution of the effect size. Declarations Data availability The data supporting the findings of this study are provided in Supplementary Table 1 . The material supporting the findings of this study is available from the corresponding author on request. ACKNOWLEDGEMENTS We thank Dr. Gregory Porras, Marie-Laure Thiolat, Nathalie Biendon, Tho Hai Nguyen, and Hugues Orignac for their invaluable help conducting the reported experiments. Experiments were performed in the Service des Animaleries of the University of Bordeaux, supported by the Région Aquitaine. The synchrotron Diamond Light Source is acknowledged for providing I18 beam time (exp. SP29838). We would also like to thank Tina Geraki for her scientific support. This study received financial support from the French government in the framework of the University of Bordeaux’s IdEx “Investments for the Future” program/GPR BRAIN_2030. This work was supported by a France Parkinson Grant (B.D.). J.S. was supported by a Région Nouvelle-Aquitaine fellowship (France). R.K. is a recipient of a Clément Fayat Foundation fellowship (France). INSERM, CNRS, and the University of Bordeaux provided financial and infrastructural support. AUTHORS CONTRIBUTIONS POF, EB and BD conceived and designed the study. EB and BD performed surgeries. JS and SD performed histological and immunohistochemical analyses of the data. RK and MLA performed imaging experiments. JS, SB and BD performed SR-XRF microscopy investigations. JS, SD, RK, MLA, SB, POF, EB and BD analyzed the data. POF, EB and BD wrote the paper. All authors discussed the results, assisted in the preparation, and contributed to the manuscript. All authors approved the final version of the document. COMPETING INTERESTS EB is a director and shareholder of Motac Neuroscience Ltd. The other authors declare no conflicts of interest. References Ramirez, A. et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 , 1184-1191, doi:10.1038/ng1884 (2006). Chien, H. F. et al. Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa-Responsive Parkinsonism Due to ATP13A2 Mutation. Neurology 97 , 763-766, doi:10.1212/WNL.0000000000012705 (2021). Kruer, M. C. & Boddaert, N. Neurodegeneration with brain iron accumulation: a diagnostic algorithm. Semin Pediatr Neurol 19 , 67-74, doi:10.1016/j.spen.2012.04.001 (2012). Yang, X. & Xu, Y. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review. Biomed Res Int 2014 , 371256, doi:10.1155/2014/371256 (2014). Park, J. S., Blair, N. F. & Sue, C. M. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms. Mov Disord 30 , 770-779, doi:10.1002/mds.26243 (2015). Gagliardi, M. et al. Mutation analysis of the ATP13A2 gene in patients with PD and MSA from Italy. J Neurol Sci 430 , 120031, doi:10.1016/j.jns.2021.120031 (2021). Estrada-Cuzcano, A. et al. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). Brain 140 , 287-305, doi:10.1093/brain/aww307 (2017). Estiar, M. A. et al. Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype. Mol Genet Genomic Med 8 , e1052, doi:10.1002/mgg3.1052 (2020). Algahtani, H. et al. Autosomal Recessive Spastic Paraplegia Type 78 Associated with a Homozygous Variant in the ATP13A2 Gene. Mov Disord Clin Pract 9 , 997-1002, doi:10.1002/mdc3.13508 (2022). Spataro, R. et al. Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion. Hum Genomics 13 , 19, doi:10.1186/s40246-019-0203-9 (2019). Dehay, B. et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A 109 , 9611-9616, doi:10.1073/pnas.1112368109 (2012). Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P. & Krainc, D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci 32 , 4240-4246, doi:10.1523/JNEUROSCI.5575-11.2012 (2012). Bento, C. F., Ashkenazi, A., Jimenez-Sanchez, M. & Rubinsztein, D. C. The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat Commun 7 , 11803, doi:10.1038/ncomms11803 (2016). van Veen, S. et al. ATP13A2 deficiency disrupts lysosomal polyamine export. Nature 578 , 419-424, doi:10.1038/s41586-020-1968-7 (2020). Murphy, K. E., Cottle, L., Gysbers, A. M., Cooper, A. A. & Halliday, G. M. ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1 , 11, doi:10.1186/2051-5960-1-11 (2013). Fujii, T. et al. Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H(+),K(+)-ATPase. Nat Commun 14 , 2174, doi:10.1038/s41467-023-37815-z (2023). van Veen, S. et al. Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders. Front Mol Neurosci 7 , 48, doi:10.3389/fnmol.2014.00048 (2014). Chen, X. et al. Cryo-EM structures and transport mechanism of human P5B type ATPase ATP13A2. Cell Discov 7 , 106, doi:10.1038/s41421-021-00334-6 (2021). Tomita, A. et al. Cryo-EM reveals mechanistic insights into lipid-facilitated polyamine export by human ATP13A2. Mol Cell 81 , 4799-4809 e4795, doi:10.1016/j.molcel.2021.11.001 (2021). Tillinghast, J., Drury, S., Bowser, D., Benn, A. & Lee, K. P. K. Structural mechanisms for gating and ion selectivity of the human polyamine transporter ATP13A2. Mol Cell 81 , 4650-4662 e4654, doi:10.1016/j.molcel.2021.10.002 (2021). Sim, S. I., von Bulow, S., Hummer, G. & Park, E. Structural basis of polyamine transport by human ATP13A2 (PARK9). Mol Cell 81 , 4635-4649 e4638, doi:10.1016/j.molcel.2021.08.017 (2021). Mu, J. et al. Conformational cycle of human polyamine transporter ATP13A2. Nat Commun 14 , 1978, doi:10.1038/s41467-023-37741-0 (2023). Malandrini, A., Rubegni, A., Battisti, C., Berti, G. & Federico, A. Electron-dense lamellated inclusions in 2 siblings with Kufor-Rakeb syndrome. Mov Disord 28 , 1751-1752, doi:10.1002/mds.25470 (2013). Schmidt, K., Wolfe, D. M., Stiller, B. & Pearce, D. A. Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem Biophys Res Commun 383 , 198-202, doi:10.1016/j.bbrc.2009.03.151 (2009). Wang, R. et al. ATP13A2 facilitates HDAC6 recruitment to lysosome to promote autophagosome-lysosome fusion. J Cell Biol 218 , 267-284, doi:10.1083/jcb.201804165 (2019). Anand, N. et al. Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function. Neurobiol Dis 139 , 104786, doi:10.1016/j.nbd.2020.104786 (2020). Heins-Marroquin, U., Jung, P. P., Cordero-Maldonado, M. L., Crawford, A. D. & Linster, C. L. Phenotypic assays in yeast and zebrafish reveal drugs that rescue ATP13A2 deficiency. Brain Commun 1 , fcz019, doi:10.1093/braincomms/fcz019 (2019). Schultheis, P. J. et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited alpha-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet 22 , 2067-2082, doi:10.1093/hmg/ddt057 (2013). Kett, L. R. et al. alpha-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2. J Neurosci 35 , 5724-5742, doi:10.1523/JNEUROSCI.0632-14.2015 (2015). Farias, F. H. et al. A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers. Neurobiol Dis 42 , 468-474, doi:10.1016/j.nbd.2011.02.009 (2011). Van den Haute, C., Eggermont, K., Nuttin, B., Debyser, Z. & Baekelandt, V. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum Gene Ther 14 , 1799-1807, doi:10.1089/104303403322611809 (2003). Barnes, L., Widdowson, P., Bezard, E., Kelleher, M. & Mitrophanous, K. Optimising lentiviral vector delivery to the brain using infusion techniques. Human Gene Therapy 22 , A80-A81 (2011). Bezard, E. et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21 , 6853-6861, doi:10.1523/JNEUROSCI.21-17-06853.2001 (2001). Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281 , 29739-29752, doi:10.1074/jbc.M600933200 (2006). Ghanem, S. S. et al. alpha-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc Natl Acad Sci U S A 119 , e2109617119, doi:10.1073/pnas.2109617119 (2022). Giasson, B. I. et al. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res 59 , 528-533, doi:10.1002/(SICI)1097-4547(20000215)59:43.0.CO;2-0 (2000). Gitler, A. D. et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41 , 308-315, doi:10.1038/ng.300 (2009). Tan, J. et al. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. J Biol Chem 286 , 29654-29662, doi:10.1074/jbc.M111.233874 (2011). Schneider, S. A. et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 25 , 979-984, doi:10.1002/mds.22947 (2010). Bruggemann, N. et al. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 67 , 1357-1363, doi:10.1001/archneurol.2010.281 (2010). Bourdenx, M. et al. Identification of distinct pathological signatures induced by patient-derived alpha-synuclein structures in nonhuman primates. Sci Adv 6 , eaaz9165, doi:10.1126/sciadv.aaz9165 (2020). Dexter, D. T. et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 , 1219-1220, doi:10.1016/s0140-6736(87)91361-4 (1987). Groger, A. & Berg, D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm (Vienna) 119 , 1523-1528, doi:10.1007/s00702-012-0873-0 (2012). Wallis, L. I. et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 28 , 1061-1067, doi:10.1002/jmri.21563 (2008). Paolicelli, R. C. et al. Microglia states and nomenclature: A field at its crossroads. Neuron 110 , 3458-3483, doi:10.1016/j.neuron.2022.10.020 (2022). Jean, L. The statistical power of three monkeys. bioRxiv , 2022.2005.2010.491373, doi:10.1101/2022.05.10.491373 (2022). Koprich, J. B., Johnston, T. H., Reyes, G., Omana, V. & Brotchie, J. M. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. PLoS One 11 , e0167235, doi:10.1371/journal.pone.0167235 (2016). McCormack, A. L. et al. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One 5 , e12122, doi:10.1371/journal.pone.0012122 (2010). Bassil, F. et al. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. Mov Disord 32 , 1230-1239, doi:10.1002/mds.27041 (2017). Mandel, R. J. et al. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun 5 , 47, doi:10.1186/s40478-017-0451-7 (2017). Marmion, D. J. et al. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis 148 , 105184, doi:10.1016/j.nbd.2020.105184 (2021). Jarraya, B. et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1 , 2ra4, doi:10.1126/scitranslmed.3000130 (2009). Palfi, S. et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22 , 4942-4954, doi:10.1523/JNEUROSCI.22-12-04942.2002 (2002). Galvan, A. et al. Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System. Hum Gene Ther 32 , 599-615, doi:10.1089/hum.2020.301 (2021). Darricau, M. et al. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain , doi:10.1093/brain/awac428 (2022). Teil, M. et al. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain 145 , 1001-1017, doi:10.1093/brain/awab374 (2022). Teil, M. et al. Cortical Lewy body injections induce long-distance pathogenic alterations in the non-human primate brain. NPJ Parkinsons Dis 9 , 135, doi:10.1038/s41531-023-00579-w (2023). Capogrosso, M. et al. A brain-spine interface alleviating gait deficits after spinal cord injury in primates. Nature 539 , 284-288, doi:10.1038/nature20118 (2016). Rosenblad, C. et al. Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease. Brain 142 , 2402-2416, doi:10.1093/brain/awz176 (2019). Arotcarena, M. L. et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 143 , 1462-1475, doi:10.1093/brain/awaa096 (2020). Fridjonsdottir, E. et al. Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Sci Adv 7 , doi:10.1126/sciadv.abe5948 (2021). Wohlke, A. et al. A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier. PLoS Genet 7 , e1002304, doi:10.1371/journal.pgen.1002304 (2011). Schmutz, I. et al. ATP13A2 missense variant in Australian Cattle Dogs with late onset neuronal ceroid lipofuscinosis. Mol Genet Metab 127 , 95-106, doi:10.1016/j.ymgme.2018.11.015 (2019). Arotcarena, M. L. et al. Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques. Front Bioeng Biotechnol 9 , 762209, doi:10.3389/fbioe.2021.762209 (2021). Chuapoco, M. R. et al. Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain. Nat Nanotechnol , doi:10.1038/s41565-023-01419-x (2023). Dehay, B., Dalkara, D., Dovero, S., Li, Q. & Bezard, E. Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. Sci Rep 2 , 253, doi:10.1038/srep00253 (2012). Bjorklund, T. & Davidsson, M. Next-Generation Gene Therapy for Parkinson's Disease Using Engineered Viral Vectors. J Parkinsons Dis 11 , S209-S217, doi:10.3233/JPD-212674 (2021). Lovaas, E. Antioxidative and metal-chelating effects of polyamines. Adv Pharmacol 38 , 119-149, doi:10.1016/s1054-3589(08)60982-5 (1997). Ha, H. C. et al. The natural polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci U S A 95 , 11140-11145, doi:10.1073/pnas.95.19.11140 (1998). Martin, S. et al. Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2. Parkinsons Dis 2016 , 9531917, doi:10.1155/2016/9531917 (2016). Levin, J. et al. Generation of ferric iron links oxidative stress to alpha-synuclein oligomer formation. J Parkinsons Dis 1 , 205-216, doi:10.3233/JPD-2011-11040 (2011). Dexter, D. T. et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 ( Pt 4) , 1953-1975, doi:10.1093/brain/114.4.1953 (1991). Rentschler, G. et al. ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese. Neurotoxicology 33 , 697-702, doi:10.1016/j.neuro.2012.01.007 (2012). Fleming, S. M. et al. The effect of manganese exposure in Atp13a2-deficient mice. Neurotoxicology 64 , 256-266, doi:10.1016/j.neuro.2017.06.005 (2018). Davies, K. M. et al. Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol Aging 35 , 858-866, doi:10.1016/j.neurobiolaging.2013.09.034 (2014). Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 72 , 8463-8471, doi:10.1128/JVI.72.11.8463-8471.1998 (1998). Deffains, M. et al. L-DOPA regulates alpha-synuclein accumulation in experimental parkinsonism. Neuropathol Appl Neurobiol 47 , 532-543, doi:10.1111/nan.12678 (2021). Rusanescu, G. & Mao, J. Immature spinal cord neurons are dynamic regulators of adult nociceptive sensitivity. J Cell Mol Med 19 , 2352-2364, doi:10.1111/jcmm.12648 (2015). Bellet, V. et al. Proteomic analysis of RCL2 paraffin-embedded tissues. J Cell Mol Med 12 , 2027-2036, doi:10.1111/j.1582-4934.2008.00186.x (2008). Blaszczyk, L. et al. Sequential alteration of microglia and astrocytes in the rat thalamus following spinal nerve ligation. J Neuroinflammation 15 , 349, doi:10.1186/s12974-018-1378-z (2018). Gustafsson, O. J., Arentz, G. & Hoffmann, P. Proteomic developments in the analysis of formalin-fixed tissue. Biochim Biophys Acta 1854 , 559-580, doi:10.1016/j.bbapap.2014.10.003 (2015). Rousseau, E. et al. Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation. Proc Natl Acad Sci U S A 101 , 9648-9653, doi:10.1073/pnas.0403015101 (2004). Solé, V. A., Papillon, E., Cotte, M., Walter, P. & Susini, J. A multiplatform code for the analysis of energy-dispersive X-ray fluorescence spectra. Spectrochimica Acta Part B: Atomic Spectroscopy 62 , 63-68, doi:https://doi.org/10.1016/j.sab.2006.12.002 (2007). Ho, J., Tumkaya, T., Aryal, S., Choi, H. & Claridge-Chang, A. Moving beyond P values: data analysis with estimation graphics. Nat Methods 16 , 565-566, doi:10.1038/s41592-019-0470-3 (2019). Additional Declarations There is a conflict of interest EB is a director and shareholder of Motac Neuroscience Ltd. The other authors declare no conflicts of interest. Supplementary Files Supp.Table1080124.xlsx Supplementary Table 1 SikoraManuscriptSupplementaryFigures080124withfigures.docx Cite Share Download PDF Status: Published Journal Publication published 01 Aug, 2024 Read the published version in npj Parkinson's Disease → Version 1 posted Editorial decision: revise 06 Mar, 2024 Review # 2 received at journal 27 Feb, 2024 Review # 3 received at journal 19 Feb, 2024 Review # 1 received at journal 08 Feb, 2024 Reviewer # 3 agreed at journal 02 Feb, 2024 Reviewer # 2 agreed at journal 24 Jan, 2024 Reviewer # 1 agreed at journal 22 Jan, 2024 Reviewers invited by journal 19 Jan, 2024 Editor assigned by journal 10 Jan, 2024 Submission checks completed at journal 09 Jan, 2024 First submitted to journal 08 Jan, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3845030","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":268063022,"identity":"69b3c1eb-0b6a-4cc1-9157-13255b2a9c6a","order_by":0,"name":"Benjamin Dehay","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0003-1723-9045","institution":"Neurodegeneratives Diseases Institute","correspondingAuthor":true,"prefix":"","firstName":"Benjamin","middleName":"","lastName":"Dehay","suffix":""},{"id":268063023,"identity":"dbe0ce8b-a979-4b61-9459-01a4d27f64c5","order_by":1,"name":"Joanna Sikora","email":"","orcid":"","institution":"Neurodegeneratives Diseases Institute","correspondingAuthor":false,"prefix":"","firstName":"Joanna","middleName":"","lastName":"Sikora","suffix":""},{"id":268063024,"identity":"591d78ae-ef26-4319-ac42-10bdaecce38d","order_by":2,"name":"Sandra Dovero","email":"","orcid":"","institution":"University of Bordeaux","correspondingAuthor":false,"prefix":"","firstName":"Sandra","middleName":"","lastName":"Dovero","suffix":""},{"id":268063025,"identity":"864a90bc-5e38-42d7-9cdd-60f94db4b6e0","order_by":3,"name":"Rémi Kinet","email":"","orcid":"https://orcid.org/0000-0002-7737-6837","institution":"Neurodegeneratives Diseases Institute","correspondingAuthor":false,"prefix":"","firstName":"Rémi","middleName":"","lastName":"Kinet","suffix":""},{"id":268063026,"identity":"3d0992b1-9a1d-4cea-8670-7ea04c18b22a","order_by":4,"name":"Marie-Laure Arotcarena","email":"","orcid":"","institution":"University of Bordeaux","correspondingAuthor":false,"prefix":"","firstName":"Marie-Laure","middleName":"","lastName":"Arotcarena","suffix":""},{"id":268063027,"identity":"614b2b22-500a-45c0-a468-d841ea4d273d","order_by":5,"name":"Sylvain Bohic","email":"","orcid":"https://orcid.org/0000-0001-6355-7592","institution":"Univ. Grenoble Alpes, Synchrotron Radiation for Biomedicine (STROBE)","correspondingAuthor":false,"prefix":"","firstName":"Sylvain","middleName":"","lastName":"Bohic","suffix":""},{"id":268063028,"identity":"158060e6-2d95-4bf3-8a95-28b5f2ff86b9","order_by":6,"name":"Erwan Bezard","email":"","orcid":"https://orcid.org/0000-0002-0410-4638","institution":"University of Bordeaux","correspondingAuthor":false,"prefix":"","firstName":"Erwan","middleName":"","lastName":"Bezard","suffix":""},{"id":268063029,"identity":"46f67cb6-609a-4d40-b8a9-c864c2a999db","order_by":7,"name":"Pierre-Olivier Fernagut","email":"","orcid":"https://orcid.org/0000-0002-7737-5439","institution":"Université de Poitiers","correspondingAuthor":false,"prefix":"","firstName":"Pierre-Olivier","middleName":"","lastName":"Fernagut","suffix":""}],"badges":[],"createdAt":"2024-01-08 09:40:54","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3845030/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3845030/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41531-024-00757-4","type":"published","date":"2024-08-01T04:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":49990008,"identity":"96804b61-db1f-4d2b-b111-9a18686f370b","added_by":"auto","created_at":"2024-01-22 18:26:25","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1603566,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDecreased ATP13A2 levels in midbrain dopamine neurons lead to a PD-like pattern of nigrostriatal degeneration.\u003c/strong\u003e (\u003cstrong\u003eA\u003c/strong\u003e) Representative images (top) and quantification (bottom) of Tyrosine Hydroxylase (TH)-positive neurons by stereological counting in the substantia nigra (SN) of control and shATP13A2-injected monkeys five months after injection (SNpc: p=0.0025, t=3.814). Scale bar: 500μm (top) 200 µm (inset). (\u003cstrong\u003eB\u003c/strong\u003e) Illustrative images (left) and scatter plots (right) of striatal TH, AADC and DAT immunostaining in control and shATP13A2-injected monkeys, expressed as a percentage of controls (TH put: p=0.0038, t=3.947; TH cd: p=0.00605, t=3.548; AADC put: p=0.0001, t=10.45; AADC cd: p=0.0001, t=10.04; DAT put: p=0.0557, t=1.866; DAT cd: p=0.0129, t=2.944). Scale bars = 5mm. Each dot represents one hemisphere of the control (black) and shATP13A2-injected NHPs (red). The horizontal line indicates the average value per group ± SD. The bootstrapped mean difference with 95% CI (error bar) is shown on the right side of each graph. Comparisons were made using unpaired t-tests, *p-value\u0026lt;0.05.\u003c/p\u003e","description":"","filename":"Figure1291123.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3845030/v1/2207d89514bbcb8441ed5673.jpg"},{"id":49990009,"identity":"ff057020-dc33-4cb8-9e76-1c599debe468","added_by":"auto","created_at":"2024-01-22 18:26:25","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":693503,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDecreased ATP13A2 levels induce a-syn pathology in substantia nigra.\u003c/strong\u003e (\u003cstrong\u003eA\u003c/strong\u003e) Representative nigral sections of endogenous a-syn immunostaining (top) and scatter plot (bottom) of the mean grey value of syn211 immunostaining in the substantia nigra of control and shATP13A2-injected NHPs by quantification of surface staining, expressed as a percentage of controls monkeys (p=0.16355, t=1.067). Scale bar: 200 µm (\u003cstrong\u003eB\u003c/strong\u003e) Illustrative photomicrographs (top) and quantification (bottom) of phosphorylated S129 a-synuclein in the SNpc of control and shATP13A2-injected NHPs (p=0.0109, t=3.077). Scale bars = 100 µm (left, sections) and 10 µm (right, insets). (\u003cstrong\u003eC\u003c/strong\u003e) Midbrain protein extracts were analysed by dot-blot assay on nitrocellulose membrane and revealed by immunoblot with syn211 (p=0.0528, t=1.972) and pSyn (p=0.0001, t=13.39) antibodies. Each dot represents one hemisphere of the control (black) and shATP13A2-injected NHPs (red). Bootstrapped mean difference with 95% CI (error bar) is shown on the right side of each graph. Comparisons were made using an unpaired t-test. *p-value\u0026lt;0.05 compared to control animals.\u003c/p\u003e","description":"","filename":"Figure2291123.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3845030/v1/c543f3139ec4ce221a351fdd.jpg"},{"id":49990011,"identity":"43e51c4a-2b69-4255-be99-814bc438961a","added_by":"auto","created_at":"2024-01-22 18:26:25","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":2060084,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAccumulation of lysosomal-related structures after reduction of ATP13A2 levels. (A) \u003c/strong\u003eRepresentative nigral sections of endogenous LAMP2 immunostaining in TH-positive cells (top) and scatter plot (bottom) depicting the average number of LAMP2-positive puncta in the whole cell area (p=0.0099, t=3.004), the perinuclear (p=0.0042, t=3.631) and cytosolic (p=0.0139, t=2.768) area as well as the LAMP2-positive puncta area in the whole cell (p=0.2547, t=0.6951), the perinuclear (p=0.0256, t=0.6907) and cytosolic (p=0.25605, t=0.6905) area. \u003cstrong\u003e(B)\u003c/strong\u003eRepresentative nigral sections of endogenous LC3 immunostaining in TH-positive cells (top) and scatter plot (bottom) depicting the average number of LC3-positive puncta in the whole cell area (p=0.02435, t=2.322), the perinuclear (p=0.0172, t=2.546) and cytosolic (p=0.0382, t=2.034) area as well as the LC3-positive puncta area in the whole cell (p=0.01025, t=2.880), the perinuclear (p=0.01025, t=2.882) and cytosolic (p=0.00995, t=2.900) area. Scale bar: 10 µm. Each dot represents one hemisphere of the control (black) and shATP13A2-injected NHPs (red). Bootstrapped mean difference with 95% CI (error bar) is shown on the right side of each graph. Comparisons were made using an unpaired t-test. *p-value\u0026lt;0.05 compared to control animals.\u003c/p\u003e","description":"","filename":"Figure3291123.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3845030/v1/fe1221b114801632bcf53acb.jpg"},{"id":49990012,"identity":"c850d688-ec90-4fcd-a4b9-d37c537130be","added_by":"auto","created_at":"2024-01-22 18:26:25","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":623482,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDecreased ATP13A2 levels alter SN heavy metal concentrations. (A) \u003c/strong\u003eRepresentative elemental mapping in nigral slices of the monkey groups. Levels of iron \u003cstrong\u003e(B)\u003c/strong\u003e, sulfur \u003cstrong\u003e(C)\u003c/strong\u003e, manganese \u003cstrong\u003e(D)\u003c/strong\u003e, copper \u003cstrong\u003e(E)\u003c/strong\u003e, calcium \u003cstrong\u003e(F)\u003c/strong\u003e, and zinc \u003cstrong\u003e(G)\u003c/strong\u003e were measured using synchrotron X-ray fluorescence in the SN of control and shATP13A2-injected monkeys (Iron: p=0.0022, t=4.908; Zinc: p=0.1292, t=1.275; Copper: p=0.0028, t=4.644; Calcium: p=0.15715, t=1.118; Manganese: p=0.0011, t=5.785; Sulfur: p=0.0038, t=4.322). Each dot represents one hemisphere of the control (black) and shATP13A2-injected NHPs (red). Bootstrapped mean difference with 95% CI (error bar) is shown on the right side of each graph. Comparisons were made using an unpaired Student's t-test. *p-value\u0026lt;0.05 compared to control animals.\u003c/p\u003e","description":"","filename":"Figure4291123.jpg","url":"https://assets-eu.researchsquare.com/files/rs-3845030/v1/b373870ade65a36a603e3d97.jpg"},{"id":61627498,"identity":"8cda0a23-91e0-40bc-96ac-22050f920b17","added_by":"auto","created_at":"2024-08-02 07:08:03","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":5917236,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3845030/v1/c30c8e1e-cbd9-4bf8-8fd6-a2bda1e852d8.pdf"},{"id":49990010,"identity":"faf0bd4c-2291-4fec-9fd0-e411e967253c","added_by":"auto","created_at":"2024-01-22 18:26:25","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":26478,"visible":true,"origin":"","legend":"Supplementary Table 1","description":"","filename":"Supp.Table1080124.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-3845030/v1/5394d5eaa4fe12d17a77d0f9.xlsx"},{"id":49990014,"identity":"d810e03b-25fa-4c65-8271-eb4552da9ed1","added_by":"auto","created_at":"2024-01-22 18:26:25","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":7293887,"visible":true,"origin":"","legend":"","description":"","filename":"SikoraManuscriptSupplementaryFigures080124withfigures.docx","url":"https://assets-eu.researchsquare.com/files/rs-3845030/v1/9e98755d2fa87dbb1179db53.docx"}],"financialInterests":"There is a conflict of interest\nEB is a director and shareholder of Motac Neuroscience Ltd. The other authors declare no conflicts of interest.","formattedTitle":"Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in non-human primates","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eThe \u003cem\u003eATP13A2\u003c/em\u003e gene (OMIM#610513) encodes a transmembrane lysosomal 5 P-type ATPase. The first mutations described in \u003cem\u003eATP13A2\u003c/em\u003e cause an autosomal recessive form of early-onset parkinsonism called Kufor-Rakeb Syndrome (KRS, OMIM#606693) \u003csup\u003e1\u003c/sup\u003e and neuronal ceroid lipofuscinosis (NCL, OMIM#256730), later assigned to PARK9 locus. The clinical spectrum of KRS comprises parkinsonism, dystonia, supranuclear gaze palsy, and severe cognitive decline \u003csup\u003e2\u003c/sup\u003e. Brain MRI of KRS patients revealed generalised atrophy and putaminal and caudate iron accumulation, classifying KRS amongst neurodegeneration with brain iron accumulation (NBIA) \u003csup\u003e3\u003c/sup\u003e. NCL is a lysosomal storage disorder (LSD) that belongs to a genetically heterogeneous group of rare neurodegenerative diseases resulting from an accumulation of lipopigments, predominantly in the brain and retina. Typical clinical manifestations of these LSDs include progressive motor and cognitive impairment, seizures, and visual impairment or blindness. The outcome is invariably fatal, usually during the second or third decade.\u003c/p\u003e \u003cp\u003eToday, there is a growing list of homozygous and compound-heterozygous mutations \u003csup\u003e4,5\u003c/sup\u003e linked to the truncation of the ATP13A2 protein, resulting in a loss of its functional capabilities. Remarkably, all mutations associated with KRS that have undergone experimental scrutiny exhibit varying degrees of interference with ATP13A2 function. These disruptions are brought about through diverse mechanisms, including nonsense-mediated messenger RNA decay, protein mislocalization, and premature degradation of protein products by the proteasomal system. However, the phenotypic spectrum associated with genetic variants in \u003cem\u003eATP13A2\u003c/em\u003e now becomes more and more complex since the (partial) loss of function leads to a whole range of clinical phenotypes, including previously comprised of KRS, NCL, multiple system atrophy (MSA) \u003csup\u003e6\u003c/sup\u003e, hereditary spastic paraplegia (SPG78) \u003csup\u003e7\u0026ndash;9\u003c/sup\u003e, and juvenile-onset amyotrophic lateral sclerosis (ALS) \u003csup\u003e10\u003c/sup\u003e, as supported by both genetic and functional data, which makes the \u003cem\u003eATP13A2\u003c/em\u003e gene a puzzling gene. To date, neuroprotective strategies for all those diseases that would stop or slow down the yet unrelenting ATP13A2-related degenerative process are eagerly awaited.\u003c/p\u003e \u003cp\u003eMechanistic studies have previously reported that KRS-linked mutations in \u003cem\u003eATP13A2\u003c/em\u003e lead to several lysosomal alterations in \u003cem\u003eATP13A2\u003c/em\u003e KRS patient-derived fibroblasts, including impaired lysosomal acidification, decreased proteolytic processing of lysosomal enzymes, reduced degradation of lysosomal substrates and diminished lysosomal-mediated clearance of autophagosomes \u003csup\u003e11\u0026ndash;14\u003c/sup\u003e. In addition, ATP13A2 levels are decreased in nigral dopaminergic neurons from sporadic Parkinson\u0026rsquo;s disease (PD) patients \u003csup\u003e11\u003c/sup\u003e, a result later corroborated by others \u003csup\u003e15\u003c/sup\u003e. Overall, those results unravel an instrumental role for ATP13A2 on lysosomal function and cell viability. Recently, the cellular function of this P-type ATPase was unmasked \u003csup\u003e14\u003c/sup\u003e as a lysosomal H\u003csup\u003e+\u003c/sup\u003e, K\u003csup\u003e+\u003c/sup\u003e-ATPase, and polyamine exporter, confirming its link to protein degradation via the lysosomal machinery \u003csup\u003e11\u0026ndash;13,16\u003c/sup\u003e and metal homeostasis (as reviewed in \u003csup\u003e17\u003c/sup\u003e), which cryo-electron microscopy has further structurally characterised \u003csup\u003e18\u0026ndash;22\u003c/sup\u003e, altogether improving our understanding behind ATP13A2-associated functions.\u003c/p\u003e \u003cp\u003eTo date, only one human brain neuropathological study from one ATP13A2-mutant KRS patient is available \u003csup\u003e2\u003c/sup\u003e, reporting widespread neuronal and glial lipofuscin accumulation and sparse iron deposits in several brain areas, with skin and muscle of KRS subjects containing electron-dense lamellated structures \u003csup\u003e23\u003c/sup\u003e. To decipher the pathological consequences of ATP13A2 deficiency, a vast spectrum of model organisms has been used, from yeast \u003csup\u003e24\u003c/sup\u003e to different animal species (fly \u003csup\u003e25\u003c/sup\u003e, worm \u003csup\u003e26\u003c/sup\u003e, zebrafish \u003csup\u003e27\u003c/sup\u003e, and mouse \u003csup\u003e28,29\u003c/sup\u003e). Atp13a2 null mice exhibit increased autofluorescence in multiple brain regions, indicative of lipofuscin accumulation and modest age-related motor dysfunction preceded by neuropathological changes, including gliosis, accumulation of ubiquitinated protein aggregates, and endolysosomal abnormalities. Still, no overt neurodegeneration and iron accumulation have been observed. Additionally, a recessive mutation has been described in canine ATP13A2, causing adult-onset NCL in Tibetan terriers where autofluorescent cytoplasmic inclusions were detected in brain tissue consistent with NCL \u003csup\u003e30\u003c/sup\u003e. Altogether, model organisms used until now with the (partial) loss of ATP13A2 exhibit subtle age-dependent motor dysfunction, which at the cellular level correlates to lysosomal impairment. In mammalian model organisms, gliosis and lipofuscinosis were additional from ATP13A2 deficiency. These findings demonstrate the significance of lysosomal functionality at the core of ATP13A2 depletion. However, to truly decipher the clinical spectrum observed in humans, the role of ATP13A2 in neuronal survival, and how this dysfunction leads to neurodegeneration, we hypothesised that, in nonhuman primates, a species phylogenetically closer to humans, targeted silencing of ATP13A2 in dopaminergic neurons might result in neuronal death, α-synuclein pathology, metal dyshomeostasis, and autophagy dysfunction.\u003c/p\u003e \u003cp\u003eTo this end, in a proof-of-concept pilot study, we injected bilaterally into the substantia nigra of macaque monkeys a lentiviral vector-mediated short-hairpin RNA (LV-shRNA) to downregulate the expression of ATP13A2. Five months after administration, we observed nigrostriatal neurodegeneration associated with α-synuclein pathology, nigral iron accumulation, and autophagy lysosomal pathway (ALP) disturbances upon LV-mediated ATP13A2 silencing.\u003c/p\u003e"},{"header":"RESULTS","content":"\u003cp\u003e \u003cb\u003eNigral ATP13A2 depletion induces nigrostriatal neurodegeneration.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThe lentiviral vector (LV) system is highly effective for delivering short hairpin RNA (shRNA) expression cassettes \u003csup\u003e31\u003c/sup\u003e associated with no indications of increased non-human primate (NHP) tissue damage or inflammatory responses \u003csup\u003e32\u003c/sup\u003e. We used a functional and efficient sequence of shRNA targeting human ATP13A2 cloned into an LV plasmid, which displayed a 95% reduction in ATP13A2 levels by immunoblotting, as previously reported \u003csup\u003e11\u003c/sup\u003e. In addition, we showed that LV-mediated ATP13A2 knockdown in primary mesencephalic dopaminergic neurons resulted in neurotoxicity \u003csup\u003e11\u003c/sup\u003e. To further determine the pathological consequences of silencing ATP13A2 in a species closer to humans, adult macaque monkeys received bilateral stereotactic injections (10\u0026micro;l per hemisphere) of LV encoding shATP13A2 into the SNpc (\u003cb\u003eSupplementary Fig.\u0026nbsp;1A\u003c/b\u003e). Five months after administration, monkeys were tested to evaluate the transduction efficiency and the integrity of the nigrostriatal pathway. ATP13A2 immunofluorescence revealed a significant decrease in ATP13A2 levels in TH-positive dopaminergic neurons of the shATP13A2 versus the control group (\u003cb\u003eSupplementary Fig.\u0026nbsp;1B\u003c/b\u003e). We confirmed a\u0026thinsp;~\u0026thinsp;60% decrease in endogenous ATP13A2 after shATP13A2 LV was obtained by immunoblot of homogenised formalin-fixed tissues collected on sections in the SNpc (\u003cb\u003eSupplementary Fig.\u0026nbsp;1C\u003c/b\u003e). shATP13A2-injected monkeys displayed a significant decrease in TH immunoreactivity in the SNpc (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA), which was accompanied by a significant reduction in striatal dopaminergic innervation both in the putamen and caudate nucleus (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). Stereological counts showed that shATP13A2-injected animals exhibited a\u0026thinsp;~\u0026thinsp;28% TH-positive cell loss in the SNpc (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). However, no overt parkinsonism was observed because the extent of the lesion remained below the threshold for the onset of motor symptoms, i.e., 45% cell loss \u003csup\u003e33\u003c/sup\u003e. At the striatal level, LV-shATP13A2 injection induced a significant 30% loss of TH immunoreactivity in the caudate nucleus \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB\u003cb\u003e)\u003c/b\u003e and 45% in the putamen \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB\u003cb\u003e)\u003c/b\u003e. AADC, the enzyme that decarboxylates L-DOPA into dopamine \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB\u003cb\u003e)\u003c/b\u003e, and striatal DAT immunostaining \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB\u003cb\u003e)\u003c/b\u003e were also both reduced, with a mean difference between groups of 60\u0026ndash;70% (AADC) and 35% (DAT) in the caudate and putamen respectively.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eATP13A2 depletion alters α-synuclein homeostasis in substantia nigra.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eWe then investigated the consequences of ATP13A2 depletion-induced nigrostriatal degeneration on nigral α-synuclein (α-syn) protein expression. We performed a quantitative post-mortem analysis of total α-syn (syn211 antibody) and phosphorylated α-syn at S129 (EP1536Y) levels as a surrogate marker of the presence of α-syn pathology \u003csup\u003e34,35\u003c/sup\u003e within the SN. In contrast to predictions from \u003cem\u003ein vitro\u003c/em\u003e studies, we observed no changes in total α-syn levels in SN (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA\u003cem\u003e)\u003c/em\u003e, while the α-syn pathogenic form, i.e., S129 phosphorylated α-syn, increased in DA neurons in shATP13A2-injected animals (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). Even though we could not obtain fresh tissues from the substantia nigra of monkeys for Western blotting analysis, we performed protein extraction from formalin-fixed substantia nigra to further investigate α-syn pathology. Notably, our findings indicated that there were no discernible changes in total α-syn levels when using the syn211 antibody on mesencephalic total protein extracts, aligning with the results obtained from the immunohistochemical analysis, which also showed a significant accumulation of phosphorylated α-synuclein (pSyn) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). The absence of modifications in total α-syn levels could potentially be attributed to a conformational alteration in the α-syn protein, causing it to adopt a pathological form that conceals the syn211 epitope (located within amino acids 121\u0026ndash;125) \u003csup\u003e36\u003c/sup\u003e. Consequently, this post-translational modification might alter its conformation and render it undetectable by the syn211 antibody while remaining accessible to the anti-p-S129 α-synuclein antibody. This phenomenon could account for the observed increase in one species coinciding with no changes in the other. To further examine the distribution of α-syn, we performed triple immunofluorescence at the nigral level with the well-established dopaminergic marker TH, the lysosomal marker LAMP1 and the Syn211 antibody (\u003cb\u003eSupplementary Fig.\u0026nbsp;2\u003c/b\u003e). We observed clustered compartments stained for LAMP1 with some clustering with α-syn in dopaminergic neurons of shATP13A2-injected animals compared to controls, suggesting a possibly aggregated form of α-syn consisting of the accumulation of pSyn, as detected by immunohistochemical and biochemical assays. Altogether, these results indicate α-syn build-up with a change in intracellular staining pattern and increased pSyn protein expression in SN five months after nigral LV-shATP13A2 injection.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eAccumulation of lysosomal-related vesicles in dopaminergic neurons of shATP13A2-injected animals.\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eIn vitro\u003c/em\u003e studies suggest that loss of ATP13A2 function leads to a rise in the number and size of lysosomes \u003csup\u003e11,12\u003c/sup\u003e, potentially as compensation for poor lysosomal function. Thus, we evaluated lysosomal-related vesicle number, surface and intracellular distribution in surviving nigral TH-positive neurons \u003cem\u003ein vivo\u003c/em\u003e by segmentation analysis of confocal images. Following cell segmentation into whole cell area, perinuclear and cytosolic regions of interest (ROI) and detection of LAMP2- and LC3-positive vesicles, we calculated the average number and area of LAMP2- and LC3-positive puncta (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Consistent with \u003cem\u003ein vitro\u003c/em\u003e reports, we found an increased number of LAMP2-positive lysosomes (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA) and an increased number and surface of LC3-positive autophagosomes (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB) in surviving nigral TH-positive neurons, consistent with a perturbation of these organelles. Strikingly, we observed an accumulation of both LAMP2- and LC3-positive puncta in the perinuclear area, which might indicate an accretion of immature and undegraded autolysosomes at this location as ATP13A2 inactivation is associated with impairment of autophagosome-lysosome fusion \u003csup\u003e25\u003c/sup\u003e. These findings are consistent with previous \u003cem\u003ein vitro\u003c/em\u003e studies and may reflect compensatory changes in the ALP following improper clearance of lysosomal substrates. Lipofuscin is a pigmented, heterogeneous byproduct of failed intracellular catabolism conventionally found within lysosomes or the cytosol in the brains of patients with \u003cem\u003eATP13A2\u003c/em\u003e mutations \u003csup\u003e23\u003c/sup\u003e. We next attempted to examine the presence of lipofuscin in the nigral sections. Compared with control animals, LV-shATP13A2 monkeys showed an increased deposition of autofluorescent storage material in the substantia nigra five months after nigral LV-shATP13A2 injection \u003cb\u003e(Supplementary Fig.\u0026nbsp;3)\u003c/b\u003e. Overall, these data indicate a dysfunction of the ALP associated with an accumulation of lipofuscin deposits characteristic of NCL.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eATP13A2 depletion alters metal homeostasis in substantia nigra.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eBecause the loss of ATP13A2 function is associated with dysregulated metal homeostasis in different experimental models \u003csup\u003e24,26,37,38\u003c/sup\u003e and KRS patients \u003csup\u003e39,40\u003c/sup\u003e, we measured nigral heavy metal levels by synchrotron radiation x-ray fluorescence (SR-XRF) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA) as previously described \u003csup\u003e41\u003c/sup\u003e. Iron (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB), sulfur (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC), and manganese (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD) concentrations were significantly increased in LV-shATP13A2 monkeys compared to control animals. In the case of copper, concentrations were statistically decreased in LV-shATP13A2 monkeys compared to control monkeys (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE), whereas no statistical differences were observed for calcium (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF) and zinc (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG). Interestingly, iron concentrations were a three-fold increase in shATP13A2 monkeys, reminiscent of human pathology \u003csup\u003e39,40,42\u0026ndash;44\u003c/sup\u003e. Next, we sought to determine the cell-type specificity and distribution of iron accumulation in the SN. We performed a triple immunofluorescence with the dopaminergic neuronal marker TH, the microglial marker Iba1, and Ferritin, the main iron-storage protein. We detected an increase of ferritin-positive cells in LV-shATP13A2 monkeys compared to controls \u003cb\u003e(Supplementary Fig.\u0026nbsp;4)\u003c/b\u003e, and we observed increased expression in iron-storage protein ferritin in both Iba1-positive microglia \u003cb\u003e(Supplementary Fig.\u0026nbsp;4A)\u003c/b\u003e and TH-positive neurons \u003cb\u003e(Supplementary Fig.\u0026nbsp;4B)\u003c/b\u003e. Upon closer examination, the iron-positive cells displayed distinctive morphological features consistent with activated microglia, including a compact soma and numerous thin processes \u003csup\u003e45\u003c/sup\u003e, indicative of an ongoing inflammatory response. This immunofluorescence analysis suggests that iron accumulates in dopaminergic neurons and microglial cells, with more abundant smaller puncta distributed in the microglia.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eDecreased ATP13A2 expression in the substantia nigra through an LV-shRNA strategy leads to major pathological features in nonhuman primates reminiscent of PD pathology. Knockdown of ATP13A2 by ~\u0026thinsp;60% in nigral dopaminergic neurons affected their integrity, as evidenced here by (i) changes of α-synuclein immunoreactivity associated with an increase of one of its pathological forms (i.e., S129 phosphorylation); (ii) a dyshomeostasis in heavy metals and (iii) occurrence of ALP alterations. All these features were prominent in the SN of shATP13A2-injected NHP, resulting in a loss of striatal dopaminergic terminals and SNpc dopaminergic neurons. Relevant to KRS, we also show that silencing of ATP13A2 induces iron accumulation in the substantia nigra. These observations indicate an instrumental role for ATP13A2 deficiency in lysosomal function, α-synuclein and heavy metal homeostasis, and eventually cell viability. This new PD model provides a mechanistic framework that recapitulates some key pathological features of ATP13A2-related diseases.\u003c/p\u003e \u003cp\u003eHowever, it is essential to acknowledge the limitations inherent in this study, foremost among them being the relatively small cohort sizes, typically consisting of only 2 to 3 animals per group. Nevertheless, this size is commonly recognised as a standard size for pilot studies in non-human primate (NHP) research, grounded in scientific considerations and ethical constraints \u003csup\u003e46\u003c/sup\u003e. Notably, our study's statistical power is diminished, a common characteristic in NHP research, where a significant proportion often involves minimal animal numbers per group, typically ranging from 2 to 4 individuals, due to cost and difficulty accessing monkeys. With two groups of two to three monkeys, either LV-shATP13A2-injected or noninjected, it is challenging to obtain for each variable homogenous results that allow giving definitive answers. Some endpoints do not reach statistical significance because of the small sample size. Hence, the importance of the Gardner\u0026ndash;Altman plots that focus upon the effect size of the difference, when any. Many studies conducted by our team and other colleagues working on NHPs have generally used these types of low group sizes \u003csup\u003e47\u0026ndash;57\u003c/sup\u003e. Our team is, however, known to involve a much larger number of NHPs when moving to definitive studies \u003csup\u003e41,58\u0026ndash;61\u003c/sup\u003e that have always confirmed experiments with lower n.\u003c/p\u003e \u003cp\u003eTo investigate the pathological consequences of ATP13A2 deficiency, a vast panel of models of ascending complexity, i.e., in human dopaminergic neuroblastoma-derived cells, mesencephalic primary cultures, mice, and dogs, have been developed. However, in ATP13A2 knockout mice, behavioural phenotype impairment and pathophysiological abnormalities are not detectable until old age (20- to 29-month-old), without overt neurodegeneration \u003csup\u003e28,29\u003c/sup\u003e, suggesting the involvement of strong compensatory mechanisms in transgenic mice. Dogs with ATP13A2 mutations show clinical signs of NCL similar to those of KRS patients, but without parkinsonism, associated with astrogliosis and autofluorescent storage material in nervous and cardiac tissues at an average age of 6 years, progressively worsening over time \u003csup\u003e30,62,63\u003c/sup\u003e. A striking result of the current study is the efficacy of the induction of dopaminergic neurodegeneration over five months, corresponding to a short duration for a study in nonhuman primates. We hypothesise that follow-up long-term studies are required to observe the occurrence of a full spectrum of behavioural deficits, including progressive motor and cognitive impairment, i.e., when the threshold of the nigrostriatal lesion for manifest PD will be reached \u003csup\u003e33\u003c/sup\u003e. Additionally, we should also target other brain regions to extend the disease modelling panel associated with ATP13A2 loss of function. A second aspect to be envisioned for future studies is to compare the effects obtained with an adeno-associated virus (AAV)-based strategy. Several advantages can be emphasised by moving to AAV due to its unique biological and biophysical properties. First, AAV is compatible with the viral capacity to carry recombinant DNA such as shRNA. Second, AAV has a diffusion advantage over LV due to its particle size, which is 25 nm in diameter, whereas LV particles are no less than 100 nm in diameter. Third, specific serotypes of AAV share the ability to cross the blood-brain barrier. They may be delivered through various administration routes, making them a powerful tool for genetic material delivery to the CNS \u003csup\u003e64\u0026ndash;66\u003c/sup\u003e. Fourth, AAV has proved safe and effective in preclinical and clinical settings and has been the virus of choice for developing gene therapies for PD \u003csup\u003e67\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eWhile this proof-of-concept study is encouraging, pending questions await future investigation in additional animals. To date, it is evident that numerous neurological disorders have been linked to ATP13A2 with diverse and complex neurological deficits, complicating our understanding of ATP13A2. However, the fact that mutations in a single lysosomal gene result in such a diversity of disease phenotypes suggests that lysosomal burden is a common thread running amongst them. Therefore, deciphering the ATP13A2-dependent cellular roles and pathways would enhance our understanding of brain physiology and the broader mechanisms underpinning neurodegeneration. First, one aspect to investigate in future studies will be the analysis of polyamine levels. Recent studies demonstrated the polyamine transport function of ATP13A2 \u003csup\u003e14\u003c/sup\u003e, which may support heavy metal chelation \u003csup\u003e68\u003c/sup\u003e and provide antioxidative effects \u003csup\u003e69\u003c/sup\u003e. Polyamine levels decline with ageing and are altered in PD patients. Analysing polyamine levels in this new experimental animal model should provide valuable information regarding the precise role of polyamines in PD, KRS, and beyond. Second, in humans, \u003cem\u003eATP13A2\u003c/em\u003e mutations cause neurodegeneration with brain iron accumulation \u003csup\u003e39\u003c/sup\u003e; in particular, KRS patients present iron deposits in the brain \u003csup\u003e39,40\u003c/sup\u003e whereas, in mammalian cells, ATP13A2 expression and transport activity protect against several heavy metals, such as manganese, zinc, and iron toxicity \u003csup\u003e37,70\u003c/sup\u003e. Our study measured an iron increase of over 300%, demonstrating a close relationship between iron accumulation and ATP13A2 depletion. Several experiments proposed that the ferric iron load accelerates α-synuclein aggregation \u003csup\u003e71\u003c/sup\u003e, and an increase in iron levels plus a decrease in ferritin can contribute to nigral degeneration \u003csup\u003e72\u003c/sup\u003e. An increased iron burden has been found in early PD stages in the SN \u003csup\u003e42\u0026ndash;44,72\u003c/sup\u003e. The pathological consequences of the increased iron SN burden could contribute to α-syn pathology, as we observed an increased nigral pSyn expression.\u003c/p\u003e \u003cp\u003eNoteworthy, we also observed a significant increase in manganese in the SN, consistent with the fact that ATP13A2 has been reported to be involved in manganese homeostasis \u003csup\u003e24,26,38\u003c/sup\u003e. This result is reminiscent of previous reports showing that ATP13A2 protects cells against manganese toxicity by transporting manganese into lysosomes; however, this protection is lost in the case of mutations in this gene \u003csup\u003e37\u003c/sup\u003e. A recent study showed that ATP13A2 polymorphism could be a risk marker for the neurotoxic effects of manganese in humans \u003csup\u003e73\u003c/sup\u003e. Both of our findings are of interest regarding the work of Fleming and colleagues that show increased manganese and iron in ATP13A2 knockout mice administered with manganese chloride compared to treated wild-type mice but also increased α-synuclein aggregation and higher lipofuscin deposits in the SN \u003csup\u003e74\u003c/sup\u003e. Of note, the copper reduction is also of interest and deserves further studies as it has been reported to be reduced in human SN dopaminergic neurons of PD and incidental Lewy body disease cases \u003csup\u003e75\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eOverall, we show that ATP13A2 depletion triggers PD/KRS-related features in nonhuman primates, with stimulating perspectives for understanding human ATP13A2 pathology \u003cem\u003eper se\u003c/em\u003e. Further studies are needed to extend our observations and appreciate the full spectrum of behavioural and pathological outcomes of ATP13A2 deficiency. Understanding the complex contribution of the dysfunctional or absent lysosomal ATP13A2 protein to ALP dysfunction, heavy metal dyshomeostasis, and neurodegeneration would likely open new therapeutic opportunities for slowing down the degenerative process in PD/KRS patients.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eEthics Statement\u003c/h2\u003e \u003cp\u003eAll experimental protocols comply with the Council Directive of 2010 (2010/63/EU) of the European Community and the National Institute of Health Guide for the Care and Use of Laboratory Animals. The proposed research has received approbation from the French Ethical Committee for Animal Research CE50 (agreement number: 50120102-s).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eRecombinant LV-shRNA plasmid and virus production\u003c/h2\u003e \u003cp\u003eshRNA lentiviral plasmids were purchased from Sigma-Aldrich. shRNAs were validated based on the Genbank human ATP13A2 sequence NM_022089. All sequences were BLAST confirmed for specificity. Synthetic DNA encoding shRNA sequences targeting human ATP13A2 were cloned into shRNA lentiviral plasmids (pLKO.1-puro) under the control of the U6 promoter. shRNA lentiviral plasmids were transfected into BE(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e)-M17 cells for 48 hours to determine the level of knockdown of gene expression by immunoblotting \u003csup\u003e11\u003c/sup\u003e. The ATP13A2 shRNA-expressing viruses have been tested as described above. The virus titers were 6.73x10\u003csup\u003e8\u003c/sup\u003e pI/ml for ATP13A2 shRNA. The shRNA sequence used in the study is CCGGGCCCATCAACTTCAAGTTCTACTCGAGTAGAACTTGAAGTTGATGGGCTTTTTG.\u003c/p\u003e \u003cp\u003eLentiviral vector production was done by the service platform for lentiviral vector production \u0026ldquo;Vect\u0026rsquo;UB\u0026rsquo; of the TMB-Core of Bordeaux University. A lentiviral vector was produced by transient transfection of 293T cells according to standard protocols. In brief, subconfluent 293T cells were co-transfected with the lentiviral genome (psPAX2) \u003csup\u003e76\u003c/sup\u003e, with an envelope coding plasmid (pMD2G-VSVG) and with vector constructs by calcium phosphate precipitation. LVs were harvested 48 hours post-transfection and concentrated by ultracentrifugation. Viral titers of pLV lentivectors were determined by transducing 293T cells with serial dilutions of viral supernatant, and EGFP expression was quantified 5 days later by flow cytometry analysis or provirus copies number by qPCR method.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eAnimals and Stereotactic Injections\u003c/h2\u003e \u003cp\u003eTwo female adult rhesus monkeys (\u003cem\u003eMacaca mulatta\u003c/em\u003e) weighing \u0026sim;6\u0026ndash;7 kg (9\u0026ndash;10 years old) were used in this study. The monkeys were housed in the animal facility of the Institute of Neurodegenerative Diseases (UMR CNRS 5293) under standard conditions (12/12 h day/night cycle, \u0026sim;60% humidity, and \u0026sim;22\u0026deg;C). Tissues from 4 to 6 additional age-matched control animals were used for post-mortem experiments when needed and available \u003csup\u003e77\u003c/sup\u003e. Bilateral intranigral LV injections of 10\u0026micro;l were performed with electrophysiological guidance considering the line passing through the anterior (AC)-posterior (PC) commissures as a reference: -7mm posterior to AC, -4mm below the AC-PC line, and 3mm lateral from midline. At the end of the experiment (5 months post-injection), as previously described \u003csup\u003e41,56,60\u003c/sup\u003e, all monkeys were euthanised by sodium pentobarbital overdose (150mg/kg iv), followed by perfusion with saline solution (containing 1% heparin) and 4% paraformaldehyde, and brains were quickly removed and processed for histological studies.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eHistological Analysis\u003c/h2\u003e \u003cdiv id=\"Sec9\" class=\"Section3\"\u003e \u003ch2\u003eDopaminergic neurodegeneration assessments\u003c/h2\u003e \u003cp\u003eTo assess the effect of ATP13A2 silencing on dopaminergic neurones and fibres, TH (tyrosine hydroxylase), AADC (Aromatic L-amino acid decarboxylase), and DAT (Dopamine Transporter) immunohistochemistry and quantifications were performed on striatal and SNpc sections as previously described \u003csup\u003e41,56,60\u003c/sup\u003e. For TH staining, anterior striatum (pre-anterior commissure) sections and a whole rostrocaudal series (1 to 12) encompassing the SNpc were selected. For AADC and DAT staining, anterior striatum (pre-anterior commissure) sections were used. Sections were incubated with mouse monoclonal TH antibody (Millipore, MAB318, 1:5000), rabbit polyclonal AADC antibody (Merck AB136, 1:1000), or rat monoclonal DAT antibody (Merck MAB369, 1:500) for one night at room temperature (RT) and revealed the next day with the corresponding peroxidase EnVision secondary antibody, followed by DAB visualisation. SNpc sections were mounted on gelatine-coated slides, counterstained with 0.1% cresyl violet solution, dehydrated and cover-slipped. Striatal sections were mounted on gelatine-coated slides, dehydrated and cover-slipped. Striatal sections were analysed by optical density (OD) in the caudate nucleus and putamen. The slides were scanned using Epson Expression 10000XL high-resolution scanner. Images were analysed using ImageJ open-source software (version 1.53) to compare mean grey levels in the caudate nucleus and putamen. TH-positive neurons of the SNpc were counted by stereology blind about the experimental condition using a Leica DM6000B microscope coupled with the Mercator software (IMASCOPE, France). The SNpc was delineated for each slide, and dissector probes for stereological counting (100x80\u0026micro;m spaced by 600x400\u0026micro;m) were applied to the map obtained. Each TH-positive cell with the nucleus included in the probe was counted following the stereological rules of exclusion \u003csup\u003e41,56,60\u003c/sup\u003e. The total number of TH-positive neurons in the whole SNpc was then assessed per hemisphere using the optical fractionator method.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eα-Synuclein pathology assessment\u003c/h2\u003e \u003cp\u003eα-synuclein status was assessed with a mouse monoclonal antibody raised against human α-syn (1:1000, ThermoFisher [Syn211], 32-8100) and another against phosphorylated α-syn (EP1536Y, Abcam, ab51253, 1:5000) as previously described \u003csup\u003e41,56,60\u003c/sup\u003e. Briefly, selected sections of all animals were explicitly identified and incubated in the same well to allow direct comparison of immunostaining intensity. Sections were incubated overnight at room temperature with the antibodies. The following day, the revelation was performed with the corresponding peroxidase EnVision secondary antibody followed by 3,3\u0026prime;-diaminobenzidine (DAB, DAKO, K346811-2) incubation. Sections were then mounted on gelatinized slides, counterstained with 0.1% cresyl violet solution, if necessary, dehydrated, and cover-slipped until further analysis. Slides were scanned with a high-resolution scanner (Panoramic Scan II, 3DHISTECH Ltd, France) at x20 magnification and on five layers spaced by 1.4\u0026micro;m each. Quantifications were estimated by immunostaining-positive surface quantification at regional levels with the Mercator software (IMASCOPE, France), as previously described \u003csup\u003e41,56,60\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe \u0026ldquo;surface\u0026rdquo; is an additional quantification method used in tissue sections. For these analyses, a specific staining process was used to keep all tissues together in the same solution during the staining process. Then, high-resolution whole colour slide images were acquired with the 3D Histech Panoramic Scanner at 20X magnification, with 5 layers in extended mode. Each image was opened in the off-line MERCATOR PRO 7.12.3 software (Explora Nova, France), and all regions of interest were mapped. The same brightness and contrast rules were systemically applied to the RGB pictures to optimise the staining\u0026rsquo;s details without any image saturation. The colour thresholding tool was then used to select the threshold corresponding to the brown colour revealed by the DAB staining. The threshold was established based on the intensity of the staining to detect the maximum DAB staining. The file of the threshold parameters was saved and applied to all measurements for each animal/staining. Before performing the quantification, the threshold was randomly applied to some images of different treatment groups to verify the accuracy of the settings. In each region, the software extracted the surface corresponding to the threshold defined. The \u0026ldquo;surface\u0026rdquo; parameter was finally expressed as a ratio of the total surface of each area of interest. This parameter has been previously used and published \u003csup\u003e78\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eImmunofluorescence and Image Analysis\u003c/h2\u003e \u003cp\u003eTo assess ATP13A2 expression and autophagy-related markers (i.e., autophagosomes and lysosomes), nigral monkey sections were incubated simultaneously with two antibodies: a mouse monoclonal antibody against TH (Millipore, MAB318, 1:5000), and, either a rabbit monoclonal antibody against ATP13A2 (Novus Bio, NB110-41486, 1:250) or a rabbit monoclonal against human LAMP1 (Genetex, GTX62434, 1:1000) or LAMP2 (Santa Cruz Biotechnology, sc-18822, 1:1000) or LC3 (NB100-2220, Novus Biological 1:1000) or human α-syn (1:1000, ThermoFisher [Syn211], 32-8100) for one night at room temperature. Incubation with secondary antibodies was done sequentially with a goat anti-mouse AlexaFluor 488 (Invitrogen, A28751, 1:400) or a goat anti-rabbit AlexaFluor 568 (Invitrogen, A11036, 1:400) 1h30 at room temperature. Sections were mounted on non-gelatinised slides, and cover slipped using fluorescent mounting media without DAPI (Vector Labs). Images were acquired using a Zeiss SP5 confocal microscope.\u003c/p\u003e \u003cp\u003eFor LAMP2 and LC3 count and area analysis in TH-positive cells at 5 months post-injection, image analysis was performed in Fiji/ImageJ. All image acquisitions and analyses were performed blinded to the researcher. Image analysis was performed in Fiji/ImageJ using custom scripts (available at \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://github.com/SoriaFN/Lysosome_analysis\u003c/span\u003e\u003cspan address=\"https://github.com/SoriaFN/Lysosome_analysis\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). Cells were segmented by manual cell selection using the TH channel. The mask was then applied to the LAMP2 and LC3 channels, where LAMP2 and LC3 staining was quantified by automatic thresholding followed by binarisation. Total staining was then normalised per cell. For subcellular localisation analysis, cytoplasmic and nuclear ROIs were manually segmented using the TH channel of single z-planes where the nucleus was clearly visible. To prevent a bias due to low cytoplasmic area and to ensure that the comparisons were made between cells with similar cytoplasmic ROIs, the analysis was subsequently performed only in cells where the ratio of cytoplasmic to nuclear ROI area was 2:1. Lysosomal-related puncta were segmented from the LAMP2 or LC3 channel, and the average number and area from the nucleus centre to the centre of mass of each lysosomal ROI was calculated. Finally, to estimate the distance to the nucleus border, the average radius of an ellipse fitted to the nuclear ROI was subtracted from the distance to the nucleus centre.\u003c/p\u003e \u003cp\u003eTo assess ferritin pattern expression, each nigral monkey section punches was made from free-floating sections and mounted on the same slide to compare the pattern between TH, Iba1 and ferritin-expressing cells in SNpc. The resulting glass slide was incubated simultaneously with a mix of antibodies, including chicken anti-TH (Abcam, ref ab76442), goat anti-Iba1 (Abcam, ref ab5076) and rabbit anti-ferritin [EPR3004Y] (Abcam, ref ab75973), all diluted at 1:1000 and incubated for one night at room temperature. Incubation with secondary antibodies was done after thorough rinses, with a mix of donkey fluorescent secondary antibodies raised against the different species (respectively anti-chicken AlexaFluor 568 (Invitrogen, A11041), anti-goat AlexaFluor 647 (Invitrogen, A21447) and anti-rabbit AlexaFluor488 (Invitrogen, A21206) diluted at 1:500 and incubated one hour at room temperature. After several rinses with PBS, a nuclear stain was made with 1:5000 diluted Hoechst solution for 30 seconds, and sections were then coverslipped using ProlongGlass fluorescent mounting media (Thermo Fischer, ref P36984). Images were acquired using a 3D-HISTECH Pannoramic Scan II with 20X objective and extended focus mode (5 layers and 7 steps).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eLipofuscin imaging\u003c/h2\u003e \u003cp\u003eFor imaging of lipofuscin, untreated free-floating nigral slices were mounted with a Vectashield Antifade Mounting Medium to observe lipofuscin autofluorescence. Images were acquired using a Leica DM6 CFS TCS SP8 confocal microscope at x63 magnification, with an excitation of 500nm and an emission of 600-650nm. Analysis was performed through ImageJ Fiji.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eBiochemical Analysis\u003c/h2\u003e \u003cdiv id=\"Sec14\" class=\"Section3\"\u003e \u003ch2\u003eProtein Extraction and immunoblot analysis\u003c/h2\u003e \u003cp\u003eWe used 2 mm\u003csup\u003e3\u003c/sup\u003e formalin-fixed tissue per animal. Tissue patches were extracted using the Qproteome FFPE TissueKit (Qiagen) \u003csup\u003e79\u0026ndash;81\u003c/sup\u003e and then quantified using the Lowry method (Biorad RC DC Protein Assay Kit) following the manufacturer's instructions. Based on total protein concentrations calculated from the assay, aliquots of tissue lysates corresponding to 20\u0026micro;g were prepared for each structure in Laemmli buffer (Tris-HCl 25mM pH 6.8, glycerol 7.5%, SDS 1%, DTT 250mM and bromophenol blue 0.05%).\u003c/p\u003e \u003cp\u003eFor immunoblot analysis, samples were then boiled at 100\u0026deg;C for 5min and loaded into a 12% SDS-PAGE gel, followed by electrophoretic transfer onto 0.2 \u0026micro;m nitrocellulose membranes (Bio-Rad, Hercules, CA, United States). Membranes were blocked in phosphate buffer saline (PBS) with 5% dry skimmed milk and probed with an antibody against ATP13A2 (Novus Bio, NB110-41486, 1:1000) overnight. Anti-β-actin (1:10 000, Sigma, A5441) was used to control equal loading. Appropriate secondary antibodies coupled to peroxidase were revealed using a Super Signal West Pico Chemiluminescent kit (Immobilon Western, Chemiluminescent HRP substrate, Millipore) and analysed with Image Lab software 5.0 (Bio-Rad, Hercules, United States). The dot blot analysis was performed as previously described \u003csup\u003e82\u003c/sup\u003e. After heating at 100\u0026deg;C for 5 min, 20 \u0026micro;g of protein extract was diluted in buffer (25 mM Tris-HCl, 200 mM Glycine, 1% SDS) and filtered through a nitrocellulose membrane (Bio-Rad, 0.2\u0026micro;m pore size). Membranes were then saturated in 5% dry milk before incubation with total α-syn (1:1000, ThermoFisher [Syn211], 32-8100) and anti-phosphorylated-α-syn at Ser129 (1:5000, Abcam [EP1536Y], ab51253). Revelation was done as described above.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eSR-XRF microscopy elemental mapping of brain tissue cryosections\u003c/h2\u003e \u003cp\u003eThe synchrotron experiments were carried out at the Diamond Light Source, Harwell Science and Innovation Campus (Didcot, UK) with 3-GeV energy of the storage ring and 300-mA currents with top-up injection mode. All SR-XRF microscopy investigations reported herein were carried out on the microfocus spectroscopy beamline (I18). The micro-XRF elemental mapping was acquired at room temperature with an incident x-ray energy set to 12 keV using a Si(111) monochromator. This resulted in an x-ray photon flux of 2 \u0026times;10\u003csup\u003e11\u003c/sup\u003e photons/s. The SN cryostat section (50\u0026micro;m in thickness) of each animal was collected from free-floating sections and mounted onto an x-ray transparent metal-free 4-\u0026micro;m-thick Ultralene foil (SPEX CertiPrep, Metuchen, NJ, USA) secured to a customised polyetheretherketone (PEEK) holder ensuring contamination-free samples and reduced x-ray scattering contribution. The samples were then left and kept at room temperature in a moisture-free box until used for analysis. The samples were affixed to a magnetic plate connected to the sample stage of the microfocus beamline. The four-element Si drift Vortex ME4 energy-dispersive detector (Hitachi High-Technologies Science America), with Xspress 3 processing electronics, was operated in the 90\u0026deg; geometry; hence, it minimizes the background signal. The sample-detector distance was fixed (75 mm). The sample was held at 45\u0026deg; to the incident X-ray beam and raster in front of the beam while the XRF spectra were collected. An area of 500 \u0026micro;m by 500 \u0026micro;m within the SNpc was mapped for each sample with a step size that matches the beam size (5 \u0026micro;m) and a dwell time of 1 s per pixel due to the low concentration of the element. A thin (100 \u0026micro;m) pellet of the National Institute of Standards and Technology (NIST) standard reference materials SRM1577c (bovine liver material, NIST, Gaithersburg, MD, USA) was measured to calibrate experimental parameters as well as a thin-film XRF reference material (AXO DRESDEN GmbH) with nanoscale uniform mass depositions in the range of ng/mm\u003csup\u003e2\u003c/sup\u003e. This was followed by elemental quantification calculated using the Fundamental Parameters (FP) approach through the open-source software PyMCA \u003csup\u003e83\u003c/sup\u003e, in which the reference material and the sample are modelled in terms of main composition, density, and thickness. The fluorescence spectrum obtained from each pixel was fitted, the elemental concentration (micrograms per gram of dry weight or parts per million) maps were generated, and an average elemental concentration of the SNpc regions was obtained.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003eFor all experiments, comparisons among means were performed using raw data Student's unpaired t-test (GraphPad Prism 10.0, San Diego, CA). Statistical significance was set at p\u0026thinsp;\u0026lt;\u0026thinsp;0.05. The debate about the need to move beyond p-value is raging. Data must be further analysed with estimation graphics \u003csup\u003e84\u003c/sup\u003e emphasising the effect size. Therefore, all data appear as estimation graphics called \u0026lsquo;Gardner\u0026ndash;Altman plots\u0026rsquo;: on the left of each graph, data of controls and sh-ATP13A2 groups are presented as scatter plots showing the observed values along with the defined descriptive statistics (mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation). Each dot represents one hemisphere of the control (shade of black) and shATP13A2-injected NHPs (shade of red). On the right of each graph is a contrast graph using the different axes to display an effect size, which means difference. Horizontally aligned with the mean of the test group, the mean difference is indicated by the black circle. The black vertical line illustrates the 95% confidence interval (CI) of the mean difference. Given the observed data, the curve shows the resampled distribution of the effect size.\u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003ch2\u003e\u003cstrong\u003eData availability\u0026nbsp;\u003c/strong\u003e\u003c/h2\u003e\n\u003cp\u003eThe data supporting the findings of this study are provided in \u003cstrong\u003eSupplementary Table 1\u003c/strong\u003e. The material supporting the findings of this study is available from the corresponding author on request.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003eACKNOWLEDGEMENTS\u0026nbsp;\u003c/h3\u003e\n\u003cp\u003eWe thank Dr. Gregory Porras, Marie-Laure Thiolat, Nathalie Biendon, Tho Hai Nguyen, and Hugues Orignac for their invaluable help conducting the reported experiments. Experiments were performed in the Service des Animaleries of the University of Bordeaux, supported by the R\u0026eacute;gion Aquitaine. The synchrotron Diamond Light Source is acknowledged for providing I18 beam time (exp. SP29838). We would also like to thank Tina Geraki for her scientific support. This study received financial support from the French government in the framework of the University of Bordeaux\u0026rsquo;s IdEx \u0026ldquo;Investments for the Future\u0026rdquo; program/GPR BRAIN_2030. This work was supported by a France Parkinson Grant (B.D.). J.S. was supported by a R\u0026eacute;gion Nouvelle-Aquitaine fellowship (France). R.K. is a recipient of a Cl\u0026eacute;ment Fayat Foundation fellowship (France). INSERM, CNRS, and the University of Bordeaux provided financial and infrastructural support.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAUTHORS CONTRIBUTIONS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePOF, EB and BD conceived and designed the study. EB and BD performed surgeries. JS and SD performed histological and immunohistochemical analyses of the data. RK and MLA performed imaging experiments. JS, SB and BD performed SR-XRF microscopy investigations. JS, SD, RK, MLA, SB, POF, EB and BD analyzed the data. POF, EB and BD wrote the paper. All authors discussed the results, assisted in the preparation, and contributed to the manuscript. All authors approved the final version of the document.\u003c/p\u003e\n\u003ch3\u003eCOMPETING INTERESTS \u0026nbsp;\u003c/h3\u003e\n\u003cp\u003eEB is a director and shareholder of Motac Neuroscience Ltd. The other authors declare no conflicts of interest.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eRamirez, A.\u003cem\u003e et al.\u003c/em\u003e Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. \u003cem\u003eNat Genet\u003c/em\u003e \u003cstrong\u003e38\u003c/strong\u003e, 1184-1191, doi:10.1038/ng1884 (2006).\u003c/li\u003e\n\u003cli\u003eChien, H. F.\u003cem\u003e et al.\u003c/em\u003e Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa-Responsive Parkinsonism Due to ATP13A2 Mutation. \u003cem\u003eNeurology\u003c/em\u003e \u003cstrong\u003e97\u003c/strong\u003e, 763-766, doi:10.1212/WNL.0000000000012705 (2021).\u003c/li\u003e\n\u003cli\u003eKruer, M. C. \u0026amp; Boddaert, N. Neurodegeneration with brain iron accumulation: a diagnostic algorithm. \u003cem\u003eSemin Pediatr Neurol\u003c/em\u003e \u003cstrong\u003e19\u003c/strong\u003e, 67-74, doi:10.1016/j.spen.2012.04.001 (2012).\u003c/li\u003e\n\u003cli\u003eYang, X. \u0026amp; Xu, Y. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review. \u003cem\u003eBiomed Res Int\u003c/em\u003e \u003cstrong\u003e2014\u003c/strong\u003e, 371256, doi:10.1155/2014/371256 (2014).\u003c/li\u003e\n\u003cli\u003ePark, J. S., Blair, N. F. \u0026amp; Sue, C. M. The role of ATP13A2 in Parkinson\u0026apos;s disease: Clinical phenotypes and molecular mechanisms. \u003cem\u003eMov Disord\u003c/em\u003e \u003cstrong\u003e30\u003c/strong\u003e, 770-779, doi:10.1002/mds.26243 (2015).\u003c/li\u003e\n\u003cli\u003eGagliardi, M.\u003cem\u003e et al.\u003c/em\u003e Mutation analysis of the ATP13A2 gene in patients with PD and MSA from Italy. \u003cem\u003eJ Neurol Sci\u003c/em\u003e \u003cstrong\u003e430\u003c/strong\u003e, 120031, doi:10.1016/j.jns.2021.120031 (2021).\u003c/li\u003e\n\u003cli\u003eEstrada-Cuzcano, A.\u003cem\u003e et al.\u003c/em\u003e Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). \u003cem\u003eBrain\u003c/em\u003e \u003cstrong\u003e140\u003c/strong\u003e, 287-305, doi:10.1093/brain/aww307 (2017).\u003c/li\u003e\n\u003cli\u003eEstiar, M. A.\u003cem\u003e et al.\u003c/em\u003e Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype. \u003cem\u003eMol Genet Genomic Med\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, e1052, doi:10.1002/mgg3.1052 (2020).\u003c/li\u003e\n\u003cli\u003eAlgahtani, H.\u003cem\u003e et al.\u003c/em\u003e Autosomal Recessive Spastic Paraplegia Type 78 Associated with a Homozygous Variant in the ATP13A2 Gene. \u003cem\u003eMov Disord Clin Pract\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 997-1002, doi:10.1002/mdc3.13508 (2022).\u003c/li\u003e\n\u003cli\u003eSpataro, R.\u003cem\u003e et al.\u003c/em\u003e Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion. \u003cem\u003eHum Genomics\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, 19, doi:10.1186/s40246-019-0203-9 (2019).\u003c/li\u003e\n\u003cli\u003eDehay, B.\u003cem\u003e et al.\u003c/em\u003e Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e109\u003c/strong\u003e, 9611-9616, doi:10.1073/pnas.1112368109 (2012).\u003c/li\u003e\n\u003cli\u003eUsenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P. \u0026amp; Krainc, D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. \u003cem\u003eJ Neurosci\u003c/em\u003e \u003cstrong\u003e32\u003c/strong\u003e, 4240-4246, doi:10.1523/JNEUROSCI.5575-11.2012 (2012).\u003c/li\u003e\n\u003cli\u003eBento, C. F., Ashkenazi, A., Jimenez-Sanchez, M. \u0026amp; Rubinsztein, D. C. The Parkinson\u0026apos;s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. \u003cem\u003eNat Commun\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, 11803, doi:10.1038/ncomms11803 (2016).\u003c/li\u003e\n\u003cli\u003evan Veen, S.\u003cem\u003e et al.\u003c/em\u003e ATP13A2 deficiency disrupts lysosomal polyamine export. \u003cem\u003eNature\u003c/em\u003e \u003cstrong\u003e578\u003c/strong\u003e, 419-424, doi:10.1038/s41586-020-1968-7 (2020).\u003c/li\u003e\n\u003cli\u003eMurphy, K. E., Cottle, L., Gysbers, A. M., Cooper, A. A. \u0026amp; Halliday, G. M. ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. \u003cem\u003eActa Neuropathol Commun\u003c/em\u003e \u003cstrong\u003e1\u003c/strong\u003e, 11, doi:10.1186/2051-5960-1-11 (2013).\u003c/li\u003e\n\u003cli\u003eFujii, T.\u003cem\u003e et al.\u003c/em\u003e Parkinson\u0026apos;s disease-associated ATP13A2/PARK9 functions as a lysosomal H(+),K(+)-ATPase. \u003cem\u003eNat Commun\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 2174, doi:10.1038/s41467-023-37815-z (2023).\u003c/li\u003e\n\u003cli\u003evan Veen, S.\u003cem\u003e et al.\u003c/em\u003e Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson\u0026apos;s disease and other neurological disorders. \u003cem\u003eFront Mol Neurosci\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, 48, doi:10.3389/fnmol.2014.00048 (2014).\u003c/li\u003e\n\u003cli\u003eChen, X.\u003cem\u003e et al.\u003c/em\u003e Cryo-EM structures and transport mechanism of human P5B type ATPase ATP13A2. \u003cem\u003eCell Discov\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, 106, doi:10.1038/s41421-021-00334-6 (2021).\u003c/li\u003e\n\u003cli\u003eTomita, A.\u003cem\u003e et al.\u003c/em\u003e Cryo-EM reveals mechanistic insights into lipid-facilitated polyamine export by human ATP13A2. \u003cem\u003eMol Cell\u003c/em\u003e \u003cstrong\u003e81\u003c/strong\u003e, 4799-4809 e4795, doi:10.1016/j.molcel.2021.11.001 (2021).\u003c/li\u003e\n\u003cli\u003eTillinghast, J., Drury, S., Bowser, D., Benn, A. \u0026amp; Lee, K. P. K. Structural mechanisms for gating and ion selectivity of the human polyamine transporter ATP13A2. \u003cem\u003eMol Cell\u003c/em\u003e \u003cstrong\u003e81\u003c/strong\u003e, 4650-4662 e4654, doi:10.1016/j.molcel.2021.10.002 (2021).\u003c/li\u003e\n\u003cli\u003eSim, S. I., von Bulow, S., Hummer, G. \u0026amp; Park, E. Structural basis of polyamine transport by human ATP13A2 (PARK9). \u003cem\u003eMol Cell\u003c/em\u003e \u003cstrong\u003e81\u003c/strong\u003e, 4635-4649 e4638, doi:10.1016/j.molcel.2021.08.017 (2021).\u003c/li\u003e\n\u003cli\u003eMu, J.\u003cem\u003e et al.\u003c/em\u003e Conformational cycle of human polyamine transporter ATP13A2. \u003cem\u003eNat Commun\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 1978, doi:10.1038/s41467-023-37741-0 (2023).\u003c/li\u003e\n\u003cli\u003eMalandrini, A., Rubegni, A., Battisti, C., Berti, G. \u0026amp; Federico, A. Electron-dense lamellated inclusions in 2 siblings with Kufor-Rakeb syndrome. \u003cem\u003eMov Disord\u003c/em\u003e \u003cstrong\u003e28\u003c/strong\u003e, 1751-1752, doi:10.1002/mds.25470 (2013).\u003c/li\u003e\n\u003cli\u003eSchmidt, K., Wolfe, D. M., Stiller, B. \u0026amp; Pearce, D. A. Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. \u003cem\u003eBiochem Biophys Res Commun\u003c/em\u003e \u003cstrong\u003e383\u003c/strong\u003e, 198-202, doi:10.1016/j.bbrc.2009.03.151 (2009).\u003c/li\u003e\n\u003cli\u003eWang, R.\u003cem\u003e et al.\u003c/em\u003e ATP13A2 facilitates HDAC6 recruitment to lysosome to promote autophagosome-lysosome fusion. \u003cem\u003eJ Cell Biol\u003c/em\u003e \u003cstrong\u003e218\u003c/strong\u003e, 267-284, doi:10.1083/jcb.201804165 (2019).\u003c/li\u003e\n\u003cli\u003eAnand, N.\u003cem\u003e et al.\u003c/em\u003e Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function. \u003cem\u003eNeurobiol Dis\u003c/em\u003e \u003cstrong\u003e139\u003c/strong\u003e, 104786, doi:10.1016/j.nbd.2020.104786 (2020).\u003c/li\u003e\n\u003cli\u003eHeins-Marroquin, U., Jung, P. P., Cordero-Maldonado, M. L., Crawford, A. D. \u0026amp; Linster, C. L. Phenotypic assays in yeast and zebrafish reveal drugs that rescue ATP13A2 deficiency. \u003cem\u003eBrain Commun\u003c/em\u003e \u003cstrong\u003e1\u003c/strong\u003e, fcz019, doi:10.1093/braincomms/fcz019 (2019).\u003c/li\u003e\n\u003cli\u003eSchultheis, P. J.\u003cem\u003e et al.\u003c/em\u003e Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited alpha-synuclein accumulation and age-dependent sensorimotor deficits. \u003cem\u003eHum Mol Genet\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e, 2067-2082, doi:10.1093/hmg/ddt057 (2013).\u003c/li\u003e\n\u003cli\u003eKett, L. R.\u003cem\u003e et al.\u003c/em\u003e alpha-Synuclein-independent histopathological and motor deficits in mice lacking the endolysosomal Parkinsonism protein Atp13a2. \u003cem\u003eJ Neurosci\u003c/em\u003e \u003cstrong\u003e35\u003c/strong\u003e, 5724-5742, doi:10.1523/JNEUROSCI.0632-14.2015 (2015).\u003c/li\u003e\n\u003cli\u003eFarias, F. H.\u003cem\u003e et al.\u003c/em\u003e A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers. \u003cem\u003eNeurobiol Dis\u003c/em\u003e \u003cstrong\u003e42\u003c/strong\u003e, 468-474, doi:10.1016/j.nbd.2011.02.009 (2011).\u003c/li\u003e\n\u003cli\u003eVan den Haute, C., Eggermont, K., Nuttin, B., Debyser, Z. \u0026amp; Baekelandt, V. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. \u003cem\u003eHum Gene Ther\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 1799-1807, doi:10.1089/104303403322611809 (2003).\u003c/li\u003e\n\u003cli\u003eBarnes, L., Widdowson, P., Bezard, E., Kelleher, M. \u0026amp; Mitrophanous, K. Optimising lentiviral vector delivery to the brain using infusion techniques. \u003cem\u003eHuman Gene Therapy\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e, A80-A81 (2011).\u003c/li\u003e\n\u003cli\u003eBezard, E.\u003cem\u003e et al.\u003c/em\u003e Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson\u0026apos;s disease. \u003cem\u003eJ Neurosci\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 6853-6861, doi:10.1523/JNEUROSCI.21-17-06853.2001 (2001).\u003c/li\u003e\n\u003cli\u003eAnderson, J. P.\u003cem\u003e et al.\u003c/em\u003e Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. \u003cem\u003eJ Biol Chem\u003c/em\u003e \u003cstrong\u003e281\u003c/strong\u003e, 29739-29752, doi:10.1074/jbc.M600933200 (2006).\u003c/li\u003e\n\u003cli\u003eGhanem, S. S.\u003cem\u003e et al.\u003c/em\u003e alpha-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e119\u003c/strong\u003e, e2109617119, doi:10.1073/pnas.2109617119 (2022).\u003c/li\u003e\n\u003cli\u003eGiasson, B. I.\u003cem\u003e et al.\u003c/em\u003e A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson\u0026apos;s disease. \u003cem\u003eJ Neurosci Res\u003c/em\u003e \u003cstrong\u003e59\u003c/strong\u003e, 528-533, doi:10.1002/(SICI)1097-4547(20000215)59:4\u0026lt;528::AID-JNR8\u0026gt;3.0.CO;2-0 (2000).\u003c/li\u003e\n\u003cli\u003eGitler, A. D.\u003cem\u003e et al.\u003c/em\u003e Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. \u003cem\u003eNat Genet\u003c/em\u003e \u003cstrong\u003e41\u003c/strong\u003e, 308-315, doi:10.1038/ng.300 (2009).\u003c/li\u003e\n\u003cli\u003eTan, J.\u003cem\u003e et al.\u003c/em\u003e Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. \u003cem\u003eJ Biol Chem\u003c/em\u003e \u003cstrong\u003e286\u003c/strong\u003e, 29654-29662, doi:10.1074/jbc.M111.233874 (2011).\u003c/li\u003e\n\u003cli\u003eSchneider, S. A.\u003cem\u003e et al.\u003c/em\u003e ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. \u003cem\u003eMov Disord\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, 979-984, doi:10.1002/mds.22947 (2010).\u003c/li\u003e\n\u003cli\u003eBruggemann, N.\u003cem\u003e et al.\u003c/em\u003e Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. \u003cem\u003eArch Neurol\u003c/em\u003e \u003cstrong\u003e67\u003c/strong\u003e, 1357-1363, doi:10.1001/archneurol.2010.281 (2010).\u003c/li\u003e\n\u003cli\u003eBourdenx, M.\u003cem\u003e et al.\u003c/em\u003e Identification of distinct pathological signatures induced by patient-derived alpha-synuclein structures in nonhuman primates. \u003cem\u003eSci Adv\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, eaaz9165, doi:10.1126/sciadv.aaz9165 (2020).\u003c/li\u003e\n\u003cli\u003eDexter, D. T.\u003cem\u003e et al.\u003c/em\u003e Increased nigral iron content in postmortem parkinsonian brain. \u003cem\u003eLancet\u003c/em\u003e \u003cstrong\u003e2\u003c/strong\u003e, 1219-1220, doi:10.1016/s0140-6736(87)91361-4 (1987).\u003c/li\u003e\n\u003cli\u003eGroger, A. \u0026amp; Berg, D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson\u0026apos;s disease? Implications from MRI and TCS studies. \u003cem\u003eJ Neural Transm (Vienna)\u003c/em\u003e \u003cstrong\u003e119\u003c/strong\u003e, 1523-1528, doi:10.1007/s00702-012-0873-0 (2012).\u003c/li\u003e\n\u003cli\u003eWallis, L. I.\u003cem\u003e et al.\u003c/em\u003e MRI assessment of basal ganglia iron deposition in Parkinson\u0026apos;s disease. \u003cem\u003eJ Magn Reson Imaging\u003c/em\u003e \u003cstrong\u003e28\u003c/strong\u003e, 1061-1067, doi:10.1002/jmri.21563 (2008).\u003c/li\u003e\n\u003cli\u003ePaolicelli, R. C.\u003cem\u003e et al.\u003c/em\u003e Microglia states and nomenclature: A field at its crossroads. \u003cem\u003eNeuron\u003c/em\u003e \u003cstrong\u003e110\u003c/strong\u003e, 3458-3483, doi:10.1016/j.neuron.2022.10.020 (2022).\u003c/li\u003e\n\u003cli\u003eJean, L. The statistical power of three monkeys. \u003cem\u003ebioRxiv\u003c/em\u003e, 2022.2005.2010.491373, doi:10.1101/2022.05.10.491373 (2022).\u003c/li\u003e\n\u003cli\u003eKoprich, J. B., Johnston, T. H., Reyes, G., Omana, V. \u0026amp; Brotchie, J. M. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson\u0026apos;s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. \u003cem\u003ePLoS One\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, e0167235, doi:10.1371/journal.pone.0167235 (2016).\u003c/li\u003e\n\u003cli\u003eMcCormack, A. L.\u003cem\u003e et al.\u003c/em\u003e Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. \u003cem\u003ePLoS One\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e, e12122, doi:10.1371/journal.pone.0012122 (2010).\u003c/li\u003e\n\u003cli\u003eBassil, F.\u003cem\u003e et al.\u003c/em\u003e Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. \u003cem\u003eMov Disord\u003c/em\u003e \u003cstrong\u003e32\u003c/strong\u003e, 1230-1239, doi:10.1002/mds.27041 (2017).\u003c/li\u003e\n\u003cli\u003eMandel, R. J.\u003cem\u003e et al.\u003c/em\u003e Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. \u003cem\u003eActa Neuropathol Commun\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e, 47, doi:10.1186/s40478-017-0451-7 (2017).\u003c/li\u003e\n\u003cli\u003eMarmion, D. J.\u003cem\u003e et al.\u003c/em\u003e Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. \u003cem\u003eNeurobiol Dis\u003c/em\u003e \u003cstrong\u003e148\u003c/strong\u003e, 105184, doi:10.1016/j.nbd.2020.105184 (2021).\u003c/li\u003e\n\u003cli\u003eJarraya, B.\u003cem\u003e et al.\u003c/em\u003e Dopamine gene therapy for Parkinson\u0026apos;s disease in a nonhuman primate without associated dyskinesia. \u003cem\u003eSci Transl Med\u003c/em\u003e \u003cstrong\u003e1\u003c/strong\u003e, 2ra4, doi:10.1126/scitranslmed.3000130 (2009).\u003c/li\u003e\n\u003cli\u003ePalfi, S.\u003cem\u003e et al.\u003c/em\u003e Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. \u003cem\u003eJ Neurosci\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e, 4942-4954, doi:10.1523/JNEUROSCI.22-12-04942.2002 (2002).\u003c/li\u003e\n\u003cli\u003eGalvan, A.\u003cem\u003e et al.\u003c/em\u003e Intracerebroventricular Administration of AAV9-PHP.B SYN1-EmGFP Induces Widespread Transgene Expression in the Mouse and Monkey Central Nervous System. \u003cem\u003eHum Gene Ther\u003c/em\u003e \u003cstrong\u003e32\u003c/strong\u003e, 599-615, doi:10.1089/hum.2020.301 (2021).\u003c/li\u003e\n\u003cli\u003eDarricau, M.\u003cem\u003e et al.\u003c/em\u003e Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. \u003cem\u003eBrain\u003c/em\u003e, doi:10.1093/brain/awac428 (2022).\u003c/li\u003e\n\u003cli\u003eTeil, M.\u003cem\u003e et al.\u003c/em\u003e Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. \u003cem\u003eBrain\u003c/em\u003e \u003cstrong\u003e145\u003c/strong\u003e, 1001-1017, doi:10.1093/brain/awab374 (2022).\u003c/li\u003e\n\u003cli\u003eTeil, M.\u003cem\u003e et al.\u003c/em\u003e Cortical Lewy body injections induce long-distance pathogenic alterations in the non-human primate brain. \u003cem\u003eNPJ Parkinsons Dis\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 135, doi:10.1038/s41531-023-00579-w (2023).\u003c/li\u003e\n\u003cli\u003eCapogrosso, M.\u003cem\u003e et al.\u003c/em\u003e A brain-spine interface alleviating gait deficits after spinal cord injury in primates. \u003cem\u003eNature\u003c/em\u003e \u003cstrong\u003e539\u003c/strong\u003e, 284-288, doi:10.1038/nature20118 (2016).\u003c/li\u003e\n\u003cli\u003eRosenblad, C.\u003cem\u003e et al.\u003c/em\u003e Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson\u0026apos;s disease. \u003cem\u003eBrain\u003c/em\u003e \u003cstrong\u003e142\u003c/strong\u003e, 2402-2416, doi:10.1093/brain/awz176 (2019).\u003c/li\u003e\n\u003cli\u003eArotcarena, M. L.\u003cem\u003e et al.\u003c/em\u003e Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. \u003cem\u003eBrain\u003c/em\u003e \u003cstrong\u003e143\u003c/strong\u003e, 1462-1475, doi:10.1093/brain/awaa096 (2020).\u003c/li\u003e\n\u003cli\u003eFridjonsdottir, E.\u003cem\u003e et al.\u003c/em\u003e Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. \u003cem\u003eSci Adv\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, doi:10.1126/sciadv.abe5948 (2021).\u003c/li\u003e\n\u003cli\u003eWohlke, A.\u003cem\u003e et al.\u003c/em\u003e A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier. \u003cem\u003ePLoS Genet\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, e1002304, doi:10.1371/journal.pgen.1002304 (2011).\u003c/li\u003e\n\u003cli\u003eSchmutz, I.\u003cem\u003e et al.\u003c/em\u003e ATP13A2 missense variant in Australian Cattle Dogs with late onset neuronal ceroid lipofuscinosis. \u003cem\u003eMol Genet Metab\u003c/em\u003e \u003cstrong\u003e127\u003c/strong\u003e, 95-106, doi:10.1016/j.ymgme.2018.11.015 (2019).\u003c/li\u003e\n\u003cli\u003eArotcarena, M. L.\u003cem\u003e et al.\u003c/em\u003e Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques. \u003cem\u003eFront Bioeng Biotechnol\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 762209, doi:10.3389/fbioe.2021.762209 (2021).\u003c/li\u003e\n\u003cli\u003eChuapoco, M. R.\u003cem\u003e et al.\u003c/em\u003e Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain. \u003cem\u003eNat Nanotechnol\u003c/em\u003e, doi:10.1038/s41565-023-01419-x (2023).\u003c/li\u003e\n\u003cli\u003eDehay, B., Dalkara, D., Dovero, S., Li, Q. \u0026amp; Bezard, E. Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. \u003cem\u003eSci Rep\u003c/em\u003e \u003cstrong\u003e2\u003c/strong\u003e, 253, doi:10.1038/srep00253 (2012).\u003c/li\u003e\n\u003cli\u003eBjorklund, T. \u0026amp; Davidsson, M. Next-Generation Gene Therapy for Parkinson\u0026apos;s Disease Using Engineered Viral Vectors. \u003cem\u003eJ Parkinsons Dis\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, S209-S217, doi:10.3233/JPD-212674 (2021).\u003c/li\u003e\n\u003cli\u003eLovaas, E. Antioxidative and metal-chelating effects of polyamines. \u003cem\u003eAdv Pharmacol\u003c/em\u003e \u003cstrong\u003e38\u003c/strong\u003e, 119-149, doi:10.1016/s1054-3589(08)60982-5 (1997).\u003c/li\u003e\n\u003cli\u003eHa, H. C.\u003cem\u003e et al.\u003c/em\u003e The natural polyamine spermine functions directly as a free radical scavenger. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e95\u003c/strong\u003e, 11140-11145, doi:10.1073/pnas.95.19.11140 (1998).\u003c/li\u003e\n\u003cli\u003eMartin, S.\u003cem\u003e et al.\u003c/em\u003e Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2. \u003cem\u003eParkinsons Dis\u003c/em\u003e \u003cstrong\u003e2016\u003c/strong\u003e, 9531917, doi:10.1155/2016/9531917 (2016).\u003c/li\u003e\n\u003cli\u003eLevin, J.\u003cem\u003e et al.\u003c/em\u003e Generation of ferric iron links oxidative stress to alpha-synuclein oligomer formation. \u003cem\u003eJ Parkinsons Dis\u003c/em\u003e \u003cstrong\u003e1\u003c/strong\u003e, 205-216, doi:10.3233/JPD-2011-11040 (2011).\u003c/li\u003e\n\u003cli\u003eDexter, D. T.\u003cem\u003e et al.\u003c/em\u003e Alterations in the levels of iron, ferritin and other trace metals in Parkinson\u0026apos;s disease and other neurodegenerative diseases affecting the basal ganglia. \u003cem\u003eBrain\u003c/em\u003e \u003cstrong\u003e114 ( Pt 4)\u003c/strong\u003e, 1953-1975, doi:10.1093/brain/114.4.1953 (1991).\u003c/li\u003e\n\u003cli\u003eRentschler, G.\u003cem\u003e et al.\u003c/em\u003e ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese. \u003cem\u003eNeurotoxicology\u003c/em\u003e \u003cstrong\u003e33\u003c/strong\u003e, 697-702, doi:10.1016/j.neuro.2012.01.007 (2012).\u003c/li\u003e\n\u003cli\u003eFleming, S. M.\u003cem\u003e et al.\u003c/em\u003e The effect of manganese exposure in Atp13a2-deficient mice. \u003cem\u003eNeurotoxicology\u003c/em\u003e \u003cstrong\u003e64\u003c/strong\u003e, 256-266, doi:10.1016/j.neuro.2017.06.005 (2018).\u003c/li\u003e\n\u003cli\u003eDavies, K. M.\u003cem\u003e et al.\u003c/em\u003e Copper pathology in vulnerable brain regions in Parkinson\u0026apos;s disease. \u003cem\u003eNeurobiol Aging\u003c/em\u003e \u003cstrong\u003e35\u003c/strong\u003e, 858-866, doi:10.1016/j.neurobiolaging.2013.09.034 (2014).\u003c/li\u003e\n\u003cli\u003eDull, T.\u003cem\u003e et al.\u003c/em\u003e A third-generation lentivirus vector with a conditional packaging system. \u003cem\u003eJ Virol\u003c/em\u003e \u003cstrong\u003e72\u003c/strong\u003e, 8463-8471, doi:10.1128/JVI.72.11.8463-8471.1998 (1998).\u003c/li\u003e\n\u003cli\u003eDeffains, M.\u003cem\u003e et al.\u003c/em\u003e L-DOPA regulates alpha-synuclein accumulation in experimental parkinsonism. \u003cem\u003eNeuropathol Appl Neurobiol\u003c/em\u003e \u003cstrong\u003e47\u003c/strong\u003e, 532-543, doi:10.1111/nan.12678 (2021).\u003c/li\u003e\n\u003cli\u003eRusanescu, G. \u0026amp; Mao, J. Immature spinal cord neurons are dynamic regulators of adult nociceptive sensitivity. \u003cem\u003eJ Cell Mol Med\u003c/em\u003e \u003cstrong\u003e19\u003c/strong\u003e, 2352-2364, doi:10.1111/jcmm.12648 (2015).\u003c/li\u003e\n\u003cli\u003eBellet, V.\u003cem\u003e et al.\u003c/em\u003e Proteomic analysis of RCL2 paraffin-embedded tissues. \u003cem\u003eJ Cell Mol Med\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 2027-2036, doi:10.1111/j.1582-4934.2008.00186.x (2008).\u003c/li\u003e\n\u003cli\u003eBlaszczyk, L.\u003cem\u003e et al.\u003c/em\u003e Sequential alteration of microglia and astrocytes in the rat thalamus following spinal nerve ligation. \u003cem\u003eJ Neuroinflammation\u003c/em\u003e \u003cstrong\u003e15\u003c/strong\u003e, 349, doi:10.1186/s12974-018-1378-z (2018).\u003c/li\u003e\n\u003cli\u003eGustafsson, O. J., Arentz, G. \u0026amp; Hoffmann, P. Proteomic developments in the analysis of formalin-fixed tissue. \u003cem\u003eBiochim Biophys Acta\u003c/em\u003e \u003cstrong\u003e1854\u003c/strong\u003e, 559-580, doi:10.1016/j.bbapap.2014.10.003 (2015).\u003c/li\u003e\n\u003cli\u003eRousseau, E.\u003cem\u003e et al.\u003c/em\u003e Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e101\u003c/strong\u003e, 9648-9653, doi:10.1073/pnas.0403015101 (2004).\u003c/li\u003e\n\u003cli\u003eSol\u0026eacute;, V. A., Papillon, E., Cotte, M., Walter, P. \u0026amp; Susini, J. A multiplatform code for the analysis of energy-dispersive X-ray fluorescence spectra. \u003cem\u003eSpectrochimica Acta Part B: Atomic Spectroscopy\u003c/em\u003e \u003cstrong\u003e62\u003c/strong\u003e, 63-68, doi:https://doi.org/10.1016/j.sab.2006.12.002 (2007).\u003c/li\u003e\n\u003cli\u003eHo, J., Tumkaya, T., Aryal, S., Choi, H. \u0026amp; Claridge-Chang, A. Moving beyond P values: data analysis with estimation graphics. \u003cem\u003eNat Methods\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e, 565-566, doi:10.1038/s41592-019-0470-3 (2019).\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"npj-parkinsons-disease","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"npjparkd","sideBox":"Learn more about [npj Parkinson's Disease](http://www.nature.com/npjparkd/)","snPcode":"41531","submissionUrl":"https://submission.springernature.com/new-submission/41531/3","title":"npj Parkinson's Disease","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"NPJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"lysosome, neurodegeneration, synuclein, Parkinson's disease, nonhuman primate","lastPublishedDoi":"10.21203/rs.3.rs-3845030/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3845030/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eLysosomal impairment is strongly implicated in Parkinson's disease (PD). Among the several PD-linked genes, the \u003cem\u003eATP13A2\u003c/em\u003e gene, associated with the PARK9 locus, encodes a transmembrane lysosomal P5-type ATPase that acts as a lysosomal polyamine exporter. Mutations in the \u003cem\u003eATP13A2\u003c/em\u003e gene were primarily identified as the cause of Kufor-Rakeb syndrome (KRS), a juvenile-onset form of PD. Subsequently, an increasing list of several homozygous and compound-heterozygous mutations has been described. These mutations result in truncation of the ATP13A2 protein, leading to a loss of function but surprisingly causing heterogeneity and variability in the clinical symptoms associated with different brain pathologies. \u003cem\u003eIn vitro\u003c/em\u003e studies show that its loss compromises lysosomal function, contributing to cell death. To understand the role of ATP13A2 dysfunction in disease, we disrupted its expression through a viral vector-based approach in nonhuman primates. Here, in this pilot study, we injected bilaterally into the substantia nigra of macaque monkeys, a lentiviral vector expressing an ATP13A2 small hairpin RNA. Animals were terminated five months later, and brains were harvested to evaluate cerebral pathological markers known to be affected in KRS and PD. We characterised the pattern of dopaminergic loss in the striatum and the substantia nigra, the regional distribution of α-synuclein immunoreactivity in several brain structures, and its pathological status (i.e., S129 phosphorylation), the accumulation of heavy metals in nigral sections and occurrence of lysosomal dysfunction. Our findings show that lentivirus-mediated ATP13A2 silencing can induce significant and ongoing degeneration in the nigrostriatal pathway, α-synuclein pathology, and iron accumulation in nonhuman primates.\u003c/p\u003e","manuscriptTitle":"Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in non-human primates","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-01-22 18:26:20","doi":"10.21203/rs.3.rs-3845030/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2024-03-06T09:05:35+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-02-27T21:30:16+00:00","index":2,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-02-19T19:39:50+00:00","index":3,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-02-08T15:31:35+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-02-02T13:49:21+00:00","index":3,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-01-24T08:10:17+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-01-22T15:02:12+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2024-01-19T14:09:28+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-01-10T22:28:25+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-01-09T08:01:33+00:00","index":"","fulltext":""},{"type":"submitted","content":"npj Parkinson's Disease","date":"2024-01-08T09:36:34+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"npj-parkinsons-disease","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"npjparkd","sideBox":"Learn more about [npj Parkinson's Disease](http://www.nature.com/npjparkd/)","snPcode":"41531","submissionUrl":"https://submission.springernature.com/new-submission/41531/3","title":"npj Parkinson's Disease","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"NPJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5e9d77ea-7fbe-4ff7-a763-84432b0895e2","owner":[],"postedDate":"January 22nd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":28248430,"name":"Biological sciences/Neuroscience/Diseases of the nervous system/Parkinson's disease"},{"id":28248431,"name":"Biological sciences/Neuroscience/Diseases of the nervous system/Neurodegeneration"},{"id":28248432,"name":"Health sciences/Diseases/Neurological disorders/Neurodegenerative diseases/Parkinson's disease"}],"tags":[],"updatedAt":"2024-08-02T07:07:56+00:00","versionOfRecord":{"articleIdentity":"rs-3845030","link":"https://doi.org/10.1038/s41531-024-00757-4","journal":{"identity":"npj-parkinsons-disease","isVorOnly":false,"title":"npj Parkinson's Disease"},"publishedOn":"2024-08-01 04:00:00","publishedOnDateReadable":"August 1st, 2024"},"versionCreatedAt":"2024-01-22 18:26:20","video":"","vorDoi":"10.1038/s41531-024-00757-4","vorDoiUrl":"https://doi.org/10.1038/s41531-024-00757-4","workflowStages":[]},"version":"v1","identity":"rs-3845030","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3845030","identity":"rs-3845030","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}